Patent Grant
9075042
The present disclosure relates to a clinical diagnostic system, including a clinical diagnostic instrument with a disposable cartridge useful for completing diagnostic analysis in a fast and efficient manner in a clinical setting. In particular, a disposable cartridge is disclosed that is suitable for use with a clinical or diagnostic point-of-care device and capable of performing diagnostic and analytical functions including filtering samples such as plasma from whole blood and running assays and collecting measurements of analytes or biomarkers.
Clinical laboratory testing requires devices and tests with high accuracy and precision. Containing costs for lab tests is also important. Some clinical lab tests are conducted in high volume because of the large number of patients undergoing tests. There are drawbacks associated with present procedures that require sequential and additional steps and transfers of multiple reagents to produce the assay. Each additional step for a detection assay increases the degree of difficulty for execution and may even increase chances of contamination or error by the operator and is prone to misuse, thereby, resulting in a higher margin for error. Thus, it is desirable to have a clinical diagnostic device that can reduce the undesirable processing steps of transferring samples to labs and instead complete a diagnostic test in a physician's office or at a patient's bedside. Such a device would inevitably reduce processing costs and cut down on opportunity for error and contamination.
The disclosure relates generally to a clinical diagnostic system, including a clinical diagnostic instrument with a disposable cartridge useful for completing diagnostic analysis in a fast and efficient manner in a clinical setting.
In one embodiment, the disclosure relates to a multi-layer seal, comprising a barrier layer to reduce (or prevent) evaporation of liquids stored in a disposable cartridge; and a laminating element, wherein the laminating element joins the barrier layer to the disposable cartridge to seal the liquids and/or dry reagents within the disposable cartridge.
In some embodiments, the disclosure relates generally to a multi-layer seal, wherein the laminating element is made from a material chosen from a heat seal coating, a pressure sensitive adhesive (PSA), a pressure sensitive adhesive tape, a thermal adhesive, a transfer tape, a transfer adhesive, a double-sided tape, a tie layer, and an adhesive film.
In some embodiments, the disclosure relates generally to a multi-layer seal, wherein the laminating element is made from a pressure sensitive adhesive (PSA).
In some embodiments, the disclosure relates generally to a multi-layer seal, wherein the barrier layer is made from a material with low moisture vapor transmission rate.
In some embodiments, the disclosure relates generally to a multi-layer seal, wherein the barrier layer is made from a material with a moisture vapor transmission rate that is at least two times (2×) lower than a material used to form the disposable cartridge.
In some embodiments, the disclosure relates generally to a multi-layer seal, wherein the barrier layer is made from a material chosen from aluminum foil, aluminum alloy foils, metal alloy foils, high MVTR films, high barrier films, COC films, films made of fluorinated-chlorinated resins, duplex films, and triplex films.
In some embodiments, the disclosure relates generally to a multi-layer seal, wherein the barrier layer is made from aluminum foil.
In some embodiments, the disclosure relates generally to a multi-layer seal, wherein the barrier layer is puncturable.
In some embodiments, the disclosure relates generally to a multi-layer seal, wherein the multi-layer seal is a lid that seals at least one reagent handling station.
In another embodiment, the disclosure provides a multi-layer film structure, comprising a septum layer for establishing a fluidic connection between a disposable cartridge and at least one probe of a diagnostic instrument, wherein the multi-layer film structure is joined to the disposable cartridge; a support layer for reducing stretch of the septum layer during piercing and withdrawal of the at least one probe; and at least one laminating element that joins the septum layer to the support layer.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the septum layer is re-sealing and the support layer is substantially rigid.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the septum layer has at least one of the properties of pierceable, reversibly stretchable, elastic, reversibly compressible, self-sealing, prevents fluid and gas exchange, and seals against a probe.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the septum layer has all of the properties of pierceable, reversibly stretchable, elastic, reversibly compressible, self-sealing, prevents fluid and gas exchange, and seals against a probe.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the multi-layer film structure has at least one probe-addressable location.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the multi-layer film structure has a plurality of probe entry sites addressable by the probe at least once during operation.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the multi-layer film structure has a plurality of probe entry sites that are addressable more than once or re-usable.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the multi-layer film structure has at least one probe entry site addressable by the probe such that the probe will not pierce the septum layer (and such that a vent is formed at the probe entry site upon withdrawal of the probe).
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the multi-layer film structure has at least one probe entry site addressable by the probe which is puncturable.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the septum layer is made from a material chosen from synthetic rubber, silicone rubber, butyl rubber, natural rubber, elastomers, fluoroelastomers, copolymers of hexafluoropropylene, copolymers of vinylidene fluoride, terpolymers of tetrafluoroethylene, terpolymers of vinylidene fluoride, terpolymers of hexafluoropropylene, and perfluoromethylvinylether polymers.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the septum layer is made from silicone rubber.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the support layer has at least one of the properties of reduces stretch and tension of septum layer, adds rigidity to overall multi-layer film structure, adds stiffness to overall multi-layer film structure, re-enforces overall multi-layer film structure, has high flexural modulus, reduces elongation of the septum layer, and is puncturable.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the support layer has all of the properties of reduces stretch and tension of septum layer, adds rigidity to overall multi-layer film structure, adds stiffness to overall multi-layer film structure, re-enforces overall multi-layer film structure, reduces elongation of the septum layer, and is puncturable.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the support layer is made from a material chosen from metals, such as, aluminum, aluminum alloys, metal alloys, foils, rigid films, plastics sheeting, polytetrafluoroethylene, polyvinyl chloride, polyester, and polymers thereof.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the support layer is made from aluminum foil.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the support layer has a thickness of less than or equal to 7 mils, less than or equal to 6 mils or less than or equal to 5 mils.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the support layer has a thickness of less than or equal to 7 mils, less than or equal to 6 mils, less than or equal to 5 mils, less than or equal to 4 mils, less than or equal to 3 mils, less than or equal to 2 mils, less than or equal to 1 mils, or less than or equal to 0.5 mils.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the support layer adds stiffness to the multi-layer film structure facilitating the piercing of the septum layer by a probe.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the support layer adds stiffness to the multi-layer film structure reducing stretching of the septum layer during a probe entry or withdrawal.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the laminating element is made from a material chosen from a pressure sensitive adhesive (PSA), a thermal adhesive, a transfer tape, a transfer adhesive, a double sided tape, a tie layer, and an adhesive film.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the laminating element is made from a pressure sensitive adhesive (PSA).
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the layers of the multi-layer film are die-cuttable.
In some embodiments, the disclosure relates generally to a multi-layer film structure, wherein the multi-layer film structure is a component of a closed fluidic pathway.
In other embodiments, the disclosure relates generally to a multi-layer film structure, comprising a septum layer, a first laminating element, and a top seal, wherein the first laminating element joins the septum layer with the top seal, and the top seal is comprised of a support layer and a second laminating element, and wherein the second laminating element joins the support with the cartridge.
In other embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, the apparatus comprising a framework comprised of at least one structural member of a cartridge; at least one needle to establish a fluidic connection between the cartridge and the blood collection tube when the at least one needle pierces a septum of the blood collection tube, wherein the framework guides the blood collection tube into position such that the blood collection tube is at an angle ranging from about less than 90° to about 0° from the horizontal, wherein the dead volume in the blood collection tube is less than 25% of an initial fill volume.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the dead volume in the blood collection tube is less than 20% of an initial fill volume, less than 10% of an initial fill volume, or less than 5% of an initial fill volume.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the blood collection tube is at an angle ranging from less than 90° to about 45°, from about 45° to about 0°, from about 30° to about 0°, from about 20° to about 0°, from about 10° to about 0°, from about 7° to about 0°, from about 45° to about 20°, from about 45° to about 15°, from about 45° to about 10°, from about 35° to about 15°, from about 35° to about 10°, from about 35° to about 5°, from about 25° to about 15°, from about 25° to about 10°, from about 25° to about 5°, from about 15° to about 10°, from about 15° to about 5°, from about 10° to about 5°, from about 10° to about 7°, or from about 7° to about 5°, or from about 5° to about 0° from the horizontal.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the blood collection tube is at an angle of about 45°, about 30°, about 25°, about 20°, about 15°, about 10°, about 8°, about 7°, about 6°, about 5°, about 0° from the horizontal.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the blood collection tube is at an angle of about 7° from the horizontal.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the framework is comprised solely of a cartridge body.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the framework is comprised solely of structural members other than a cartridge body.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the framework is comprised of a combination of a cartridge body and at least one other structural member.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the framework provides a mechanism to prevent removal of the blood collection tube after the septum of the blood collection tube has been pierced.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the mechanism to prevent removal of the blood collection tube is a tang.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, the at least one needle comprising a first needle for introducing gas into the blood collection tube and a second needle for extracting blood from the blood collection tube, wherein the introduced gas facilitates blood extraction.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein a lubricant is applied to the at least one needle to further facilitate piercing of the septum of the blood collection tube.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the at least one needle is mounted in a recess within the framework.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the at least one needle is mounted in a recess within the framework and secured with an adhesive into the recess.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein after a fluidic connection is established with the cartridge, the blood is filtered by a blood filtration module within the cartridge to separate plasma out of the blood.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the apparatus is part of a closed fluidic pathway.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the apparatus is in fluidic communication with a blood filtration module and a blood collection tube.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the apparatus is in fluidic communication with a probe.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the apparatus is in fluidic communication with a probe pierced through a septum seal.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the apparatus is in fluidic communication with a probe pierced through a septum seal and a pump.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the apparatus includes a tube cover.
In some embodiments, the disclosure relates generally to an apparatus for mounting a blood collection tube to a cartridge, wherein the apparatus includes a tube cover and cartridge.
In further embodiments, the disclosure relates generally to a method of extracting blood from a blood collection tube, comprising positioning the blood collection tube containing a sample on a cartridge, the cartridge having a framework comprised of at least one structural member of the cartridge; at least two needles to establish a fluidic connection between the cartridge and blood collection tube when the at least two needles pierce a septum of the blood collection tube, wherein the framework guides the blood collection tube into position such that the blood collection tube is at an angle ranging from about less than 90° to about 0° from the horizontal; and introducing gas into a first of the at least two needles causing a displacement of the blood by the gas wherein the displaced blood flows from the blood collection tube to a second of the at least two needles.
In some embodiments, the disclosure relates generally to a method of extracting blood from a blood collection tube, wherein the second needle is in fluidic communication with a blood filtration module.
In some embodiments, the disclosure relates generally to a method of extracting blood from a blood collection tube, wherein the second needle is in fluidic communication with a blood filtration module, a fluidic channel, and a plasma cache, wherein an optical sensor detects an air liquid boundary when the plasma cache is filled.
In yet a further embodiment, the disclosure relates generally to a cartridge for use in a diagnostic system, comprising a body and a cover, wherein the body and the cover mate together; a blood collection tube mount to secure a blood collection tube to the cartridge, wherein the blood collection tube mount has at least one needle to engage the blood collection tube and form a fluidic connection between the cartridge and the blood collection tube; a blood collection tube; a blood filtration module in fluidic communication with the blood collection tube mount; and a plasma cache.
In yet a further embodiment, the disclosure relates generally to a cartridge for use in a diagnostic system, comprising: a body and a cover, wherein the body and the cover mate together; at least one reagent handling station formed from the body; a multi-layer fluidic seal to establish a liquid and air-tight seal of the at least one reagent handling station and to establish a fluidic connection with at least one probe of a diagnostic instrument in the diagnostic system; at least one fluidic channel formed from the body and sealed by a bottom seal, wherein the bottom seal defines in part the volume of the fluidic channels.
In some embodiments, the disclosure relates generally to a cartridge for use in a diagnostic system, wherein the at least one reagent handling station comprises a pocket formed in the floor of each reagent handling station.
In some embodiments, the disclosure relates generally to a cartridge for use in a diagnostic system, wherein the pocket reduces dead volume within the at least one reagent handling station when the at least one probe engages the multi-layer seal to contact a fluid contained therein and allows the probe to contact fluid within the pocket.
In some embodiments, the disclosure relates generally to a cartridge for use in a diagnostic system, wherein the at least one reagent handling station has a low moisture vapor transmission rate.
In some embodiments, the disclosure relates generally to a cartridge for use in a diagnostic system, wherein there are at least two reagent handling stations, and wherein one of the at least two reagent handling stations contains a pump storage liquid.
In some embodiments, the disclosure relates generally to a cartridge for use in a diagnostic system, wherein there are at least two reagent handling stations, and wherein one of the at least two reagent handling stations is initially empty and is for receiving waste.
In some embodiments, the disclosure relates generally to a cartridge for use in a diagnostic system, wherein there are at least two reagent handling stations, and wherein all reagent handling stations are initially filled with liquid except one, which is initially empty and is for receiving waste.
In some embodiments, the disclosure relates generally to a cartridge for use in a diagnostic system, wherein there are at least two reagent handling stations, and wherein all reagent handling stations are initially filled with ECL read buffer except one, which is initially empty and is for receiving waste.
In some embodiments, the disclosure relates generally to a cartridge for use in a diagnostic system, wherein the at least one reagent handling station is part of a closed fluidic pathway.
In some embodiments, the disclosure relates generally to a cartridge for use in a diagnostic system, wherein the at least one reagent handling station is part of a closed fluidic pathway, and wherein liquid emptied from a filled reagent handling station fills an empty reagent handling station using a closed fluidic system.
In still other embodiments, the disclosure relates generally to a cartridge for use in a diagnostic system, comprising a body and a cover, wherein the body and the cover mate together; a blood collection tube mount to secure a blood collection tube to the cartridge, wherein the blood collection tube mount has at least one needle to engage the blood collection tube and form a fluidic connection between the cartridge and the blood collection tube; at least one reagent handling station formed from the body; a multi-layer fluidic seal to establish a liquid and air-tight seal of the at least one reagent handling station and to establish a fluidic connection with at least one probe of a diagnostic instrument in the diagnostic system; at least one fluidic channel formed from the body and sealed by a bottom seal, wherein the bottom seal defines in part the volume of the fluidic channels.
In still other embodiments, the disclosure relates generally to a cartridge for use in a diagnostic system, comprising a body and a cover, wherein the body and the cover mate together; a blood collection tube mount to secure a blood collection tube to the cartridge, wherein the blood collection tube mount has at least one needle to engage the blood collection tube and form a fluidic connection between the cartridge and the blood collection tube; a blood collection tube; a blood filtration module in fluidic communication with the blood collection tube mount; and a plasma cache; at least one reagent handling station formed from the body; a multi-layer fluidic seal to establish a liquid and air-tight seal of the at least one reagent handling station and to establish a fluidic connection with at least one probe of a diagnostic instrument in the diagnostic system; at least one fluidic channel formed from the body and sealed by a bottom seal, wherein the bottom seal defines in part the volume of the fluidic channels.
In still another embodiment, the present disclosure relates generally to a method of metering a sample within a cartridge, comprising drawing a first volume of plasma from a sample reservoir into a primary channel of the cartridge, wherein the primary channel is filled up to a predetermined volume detected by an optical sensor of a diagnostic instrument; emptying any remaining plasma from the sample reservoir not used to fill the primary channel into a secondary channel using an optical sensor of the diagnostic instrument to detect an air liquid boundary; drawing a second volume of plasma from the primary channel into at least one receiver channel, wherein the second volume is a predetermined volume, wherein the process is repeated until each receiver channel holds the second volume of plasma, and wherein each of the steps performed are independent of pump accuracy.
In some embodiments, the present disclosure relates generally to a method of metering a sample within a cartridge, wherein the sample reservoir has a volume which is greater than or equal to the sum of the first and second volumes.
In some embodiments, the present disclosure relates generally to a method of metering a sample within a cartridge, wherein the sample reservoir has a volume ranging from about 125 μL to about 135 μL, about 135 μL to about 150 μL, about 150 μL to about 175 μL, and about 175 μL to about 200 μL.
In some embodiments, the present disclosure relates generally to a method of metering a sample within a cartridge, wherein the sample reservoir has a volume of about 200 μL.
In some embodiments, the present disclosure relates generally to a method of metering a sample within a cartridge, wherein the primary channel has a volume less than the sample reservoir.
In some embodiments, the present disclosure relates generally to a method of metering a sample within a cartridge, wherein the primary channel has a volume ranging from about 125 μL to about 135 μL, about 135 μL to about 150 μL, about 150 μL to about 175 μL, and about 175 μL to less than about 200 μL
In some embodiments, the present disclosure relates generally to a method of metering a sample within a cartridge, wherein the primary channel has a volume of about 150 μL.
In some embodiments, the present disclosure relates generally to a method of metering a sample within a cartridge, wherein the secondary channel has a volume less than the sample reservoir.
In some embodiments, the present disclosure relates generally to a method of metering a sample within a cartridge, wherein the secondary channel has a volume ranging from about 125 μL to about 135 μL, about 135 μL to about 150 μL, about 150 μL to about 175 μL, and about 175 μL to less than about 200 μL.
In some embodiments, the present disclosure relates generally to a method of metering a sample within a cartridge, wherein the secondary channel has a volume of about 150 μL.
In some embodiments, the present disclosure relates generally to a method of metering a sample within a cartridge, wherein the secondary channel has a volume greater than the difference in volume between the sample reservoir and the primary channel volumes.
In some embodiments, the present disclosure relates generally to a method of metering a sample within a cartridge, wherein each of the primary channel, the secondary channel and the receiver channels is fluidically connected to a pump of the diagnostic instrument using a probe pierced through a septum seal.
In still further embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, comprising drawing the sample within a fluidic channel until an optical sensor detects an air liquid transition of the sample, wherein the fluidic channel is fluidically connected to a pump; further drawing the sample into a well containing an assay reagent, and rehydrating a lyophilized reagent with the sample, wherein the well is fluidically connected to the pump and there is at least one difference in the cross sectional area between the fluidic channel and the well; and mixing until the sample with the assay reagent is substantially homogenous by back and forth pump motions, and causing the sample to flow through the differences in the cross sectional area between the fluidic channel and the well.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, wherein the changes in cross sectional area range from 0.0016 in2 to 0.0011 in2.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, wherein the sample and assay reagent mixture is substantially free of foam.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, wherein the sample and assay reagent mixture is substantially free of foam and foam-trapped beads.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, wherein the back and forth motion of the pump produces a flow of the sample of greater than 5 microliters per second.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, further comprising moving the sample and assay reagent mixture to an incubation zone.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, further comprising moving the sample and assay reagent mixture to an incubation zone and incubating the sample and assay reagent mixture.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, further comprising moving the sample and assay reagent mixture to an incubation zone using a fluidically connected pump and an optical sensor.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, comprising using at least one cartridge assay replicate in fluidic communication with the pump and a probe pierced through a septum seal.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, wherein the sample is introduced to the dry reagents slowly to reduce foaming.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, wherein each of the steps performed are independent of pump accuracy.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, wherein the mixing process is repeated one or more times corresponding to the number of cartridge assay replicates.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, wherein fluidic elements of the cartridge include the fluidic channels and wells and are fluidically connected to a metering device.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, wherein fluidic elements of the cartridge include the fluidic channels and wells and are fluidically connected to a metering device, a plasma cache, and a blood filtration module.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, further comprising measuring the volume of the sample and assay reagent mixture within the fluidic channel using a fluidically connected pump, an optical sensor to detect a first air liquid transition and a second liquid air transition.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, wherein the assay reagent is lyophilized.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, wherein the assay reagent is dried.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, wherein the assay reagent is comprised of one lyophilized pellet.
In some embodiments, the present disclosure relates generally to a method of mixing a sample within a cartridge of a diagnostic system, wherein the assay reagent is comprised of two lyophilized pellets.
In a still another embodiment, the present disclosure relates generally to a bead wash method for separating blood, plasma, and free label from beads with no human intervention within a cartridge of a diagnostic system, comprising drawing the sample containing beads within a fluidic channel until an optical sensor detects an air liquid transition of the sample, wherein the fluidic channel is fluidically connected to a pump; further drawing the sample into a portion of a fluidic pathway where a magnet of the diagnostic instrument makes contact with the portion of the fluidic pathway; contacting the magnet to the portion of the fluidic pathway to capture the beads within the sample at the portion of the fluidic pathway; aspirating a wash liquid pack from a reagent handling station probe fluidically connected to pump, wherein the pack contains segments of liquid buffer and air, and wherein the pack has cleaning qualities; dispensing the pack over the portion of the fluidic pathway with captured beads to wash the beads substantially free of sample and all unbound assay reagents; and removing the magnet from contact to fluidic pathway.
In some embodiments, the present disclosure relates generally to a bead wash method for separating blood, plasma, and free label from beads with no human intervention within a cartridge of a diagnostic system, wherein the wash liquid volume is less than 100 microliters.
In some embodiments, the present disclosure relates generally to a bead wash method for separating blood, plasma, and free label from beads with no human intervention within a cartridge of a diagnostic system, wherein the wash liquid pack comprises a staggered combination of liquid and air.
In some embodiments, the present disclosure relates generally to a bead wash method for separating blood, plasma, and free label from beads with no human intervention within a cartridge of a diagnostic system, wherein the wash liquid pack comprises a liquid-and-air combination.
In some embodiments, the present disclosure relates generally to a bead wash method for separating blood, plasma, and free label from beads with no human intervention within a cartridge of a diagnostic system, wherein the wash liquid pack comprises three liquid segments, surrounded by four air segments.
In some embodiments, the present disclosure relates generally to a bead wash method for separating blood, plasma, and free label from beads with no human intervention within a cartridge of a diagnostic system, wherein the beads are captured in a bead capture zone.
In some embodiments, the present disclosure relates generally to a bead wash method for separating blood, plasma, and free label from beads with no human intervention within a cartridge of a diagnostic system, wherein the bead wash efficiency is greater than 99%.
In some embodiments, the present disclosure relates generally to a bead wash method for separating blood, plasma, and free label from beads with no human intervention within a cartridge of a diagnostic system, comprising using a cartridge assay replicate in fluidic communication with a pump and a probe pierced through a septum seal.
In some embodiments, the present disclosure relates generally to a bead wash method for separating blood, plasma, and free label from beads with no human intervention within a cartridge of a diagnostic system, wherein the fluidic elements are fluidically connected to a metering device.
In some embodiments, the present disclosure relates generally to a bead wash method for separating blood, plasma, and free label from beads with no human intervention within a cartridge of a diagnostic system, wherein the fluidic elements are fluidically connected to a metering device, a plasma cache, and a blood filtration module.
In another embodiment, the present disclosure relates generally to a method of storing dry and liquid reagents together on a cartridge, comprising storing in the cartridge at least one liquid in at least one fluid-containing compartment of the cartridge; storing in the cartridge at least one dry reagent in at least one dry reagent-containing compartment, wherein the at least one fluid-containing compartment is adjacent to the at least one dry reagent-containing compartment on the cartridge, and wherein the cartridge has a pathway connecting the at least one dry reagent to at least one vapor from the liquid; and sealing a cartridge in an airtight package with a moisture-absorbent material, wherein the moisture-absorbent material out-competes the at least one dry reagent for water absorption that slowly diffuses from the liquid through a wall of the at least one fluid-containing compartment.
In some embodiments, the present disclosure relates generally to a method of storing dry and liquid reagents together on a cartridge, wherein the wall of the at least one fluid-containing compartment is made from a material having a low moisture vapor transmission rate.
In some embodiments, the present disclosure relates generally to a method of storing dry and liquid reagents together on a cartridge, wherein the wall of the at least one fluid-containing compartment is made from cyclic olefin copolymer.
In some embodiments, the present disclosure relates generally to a method of storing dry and liquid reagents together on a cartridge, wherein the moisture-absorbent material is a desiccant.
In some embodiments, the present disclosure relates generally to a method of storing dry and liquid reagents together on a cartridge, wherein the desiccant is DRIERITE®.
In some embodiments, the present disclosure relates generally to a method of storing dry and liquid reagents together on a cartridge, wherein the package is a foil pouch.
In another embodiment, the present disclosure relates generally to a desiccating system for a cartridge that has both stored liquids and dry reagents, comprising storing in the cartridge at least one liquid in at least one fluid-containing compartment of the cartridge; storing in the cartridge at least one dry reagent in at least one dry reagent-containing compartment; sealing a cartridge in an airtight package with a desiccant, wherein the cartridge has at least one passageway connecting the dry reagent and the cartridge exterior where a desiccant is located.
In some embodiments, the present disclosure relates generally to a desiccating system for a cartridge that has both stored liquids and dry reagents, wherein the at least one fluid-containing compartment is adjacent to the at least one dry reagent-containing compartment on the cartridge.
In some embodiments, the present disclosure relates generally to a desiccating system for a cartridge that has both stored liquids and dry reagents, wherein the at least one fluid-containing compartment is separated from the at least one dry reagent-containing compartment by a wall within the cartridge.
In some embodiments, the present disclosure relates generally to a desiccating system for a cartridge that has both stored liquids and dry reagents, wherein the at least one fluid-containing compartment is separated from the at least one dry reagent-containing compartment by a wall made of cyclic olefin copolymer.
In some embodiments, the present disclosure relates generally to a desiccating system for a cartridge that has both stored liquids and dry reagents, wherein the desiccant absorbs more water than the at least one dry reagent.
In some embodiments, the present disclosure relates generally to a desiccating system for a cartridge that has both stored liquids and dry reagents, wherein the rate of transport of water vapor to the desiccant is greater than the rate of transport of water vapor to the at least one dry reagent-containing compartment on the cartridge.
In some embodiments, the present disclosure relates generally to a desiccating system for a cartridge that has both stored liquids and dry reagents, wherein the desiccant is at least one molecular sieve.
In some embodiments, the present disclosure relates generally to a desiccating system for a cartridge that has both stored liquids and dry reagents, wherein the desiccant is silica.
It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein. The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” The use of the term/phrase “and/or” when used with a list means one or more of the listed items may be utilized, e.g., it is not limited to one or all of the elements.
This summary of the embodiments does not necessarily describe all features or necessary features of the embodiments. The embodiments may also reside in a sub-combination of the described features.
The accompanying tables and figures are incorporated in, and constitute a part of this specification.
The present disclosure provides a clinical diagnostic system 10 comprising a clinical or diagnostic point-of-care instrument 12 and a disposable vehicle, such as a disposable cartridge 14, for completing diagnostic analyses in a fast and efficient manner in a clinical setting (see, e.g.,
There are multiple aspects of the cartridge 14 that are related to a diagnostic device 12. Thus, some embodiments include a discussion of a correlating diagnostic instrument 12 as part of the whole diagnostic system 10. For example, during operation of the diagnostic system 10, the cartridge 14 can interact with various components of a diagnostic instrument 12, including, but not limited to, a closed fluidic pathway, a motion assembly, an incubator, a pump, and an electrochemical detection system (not depicted).
In certain embodiments, a disposable cartridge can be used in the preparation and processing of a sample, for example, on an electrochemiluminescence (ECL) measurement instrument that has various components and uses various methods. Some of these methods include, but are not limited to, methods of blood filtration (e.g., using tangential flow), methods for liquid-air transition detection in the channels of the cartridge, methods for aliquoting a clinical sample via segmented metering, methods for mixing reagents, methods for incubating the assay and washing the sample matrix away. These methods are all covered in further detail herein.
Certain embodiments of a cartridge use unique components and features to facilitate the efficient and accurate preparation and processing of a biological sample. For example, in various embodiments, a disposable cartridge can store both liquid and dry reagents in relatively close proximity of one another. A novel storage location and a reagent handling station can be used for storing and accessing the liquid reagents, for example. Additionally, a method of using a desiccant to outcompete dry reagents for moisture within the packaging of the disposable cartridge can keep the dry reagents anhydrous. These aspects described herein can extend the shelf life of a cartridge. Various failsafe mechanisms to prevent the use of a used or damaged cartridge are also provided herein.
The cartridge is self-contained so that the sample, i.e., the patient blood, remains within the cartridge and neither blood nor plasma contacts the diagnostic instrument or, more specifically, the probes on the diagnostic instrument. With the exception of an electrochemiluminescence (ECL) measurement readout performed within the diagnostic instrument, all processing of the diagnostic test, such as an immunoassay, is conducted within the cartridge. The diagnostic system largely uses fluid motions so that for most of the cartridge fluid motions, pressure-driven flow is used, where the pressure is created by a pump in the diagnostic instrument. All cartridge functions are tightly time controlled.
The fluidic control elements of the diagnostic instrument 12 can fluidically communicate with the cartridge 14 through a closed fluidic pathway 130 having a substantially single direction of flow (e.g., see
Cartridge Industrial Design.
The designs of certain embodiments of a diagnostic cartridge are disclosed in co-pending U.S. Design application Nos. 29/420,961 and 29/420,967, both filed on May 15, 2012, and each of which is herein incorporated by reference in its entirety. Images contained within those disclosures prescribe examples of diagnostic cartridges of the diagnostic system, and designs thereof, which relay both the function and form, and the connection between the product, the user, and the environment. Such images merely represent examples of cartridges, diagnostic systems, and the present disclosure is not limited to these particular designs.
According to various embodiments, a disposable cartridge 14 can be formed from a cover 16 and a body 18, for example, as depicted in
The cover 16 has a flat area which makes contact with and covers the body 18, effectively covering and protecting the components of the body 18. No liquid or air tight seals are needed between the cover 16 and the rest of the cartridge 14. A barcode 22 can be placed on a portion of the flat area of the cover 16 for identification as part of one of the many failsafe mechanisms incorporated into the diagnostic system 10. The cover 16 can be formed with a plurality of holes 24a, 24b in at least two rows, for example, as shown in
The cover 16 can be injected molded out of a variety of sturdy materials, such as, poly(methyl methacrylate) (PMMA), polycarbonate (PC), polycarbonate/Acrylonitrile butadiene styrene (PC/ABS) blends. It is contemplated that other materials may be used to form the cover 16 depending on desired specifications and manufacturing goals for the disposable cartridge 14, such as, for example, a polycarbonate/acrylonitrile butadiene styrene such as GE Cycoloy HC 1204HF, a polycarbonate such as Sabic Lexan (PC) EXL9134, polyethylene terephthalate (PET), polypropylene (PP), polyvinyl chloride (PVC), and Teflon. It is contemplated that other known methods of forming the cover 16 can be employed, including, but not limited to casting, rotational molding, thermoforming, compression molding, and injection molding.
In certain embodiments, the cartridge 14 can have features useful for blood filtration, assay processing regions (each region sometimes referred to as a cartridge assay replicate or CAR), probe wash areas and draw reservoirs filled with ECL read buffer (can also be referred to as a read buffer filled reagent handling station (RHS)), and a pump storage liquid filled RHS. Most of the components of the cartridge 14 are attached to the cartridge body 18, including, for example, the cartridge cover 16, a blood filter 19, at least one needle 42, 43, and multiple seals (See, e.g.,
The cartridge body 18 can be injection molded out of a variety of sturdy materials such as a low moisture vapor transmission rate (MVTR) plastic such as Topas grade AS 5013 (MVTR=0.03 g mm/(m2 day) at 23° C. and 85% RH), Topas grade 8007 (MVTR=0.025 g mm/(m2 day) at 23° C. and 85% RH), or Zeonor 1420R (MVTR=0.029 g mm/(m2 day) at 25° C. and 90% RH). It is contemplated that other materials may be used to form the body 18 depending on desired specifications and manufacturing goals for the disposable cartridge 14, including, but not limited to, high density polyethylene (HPDE), polypropylene (PP), and polyethylene terephthalate (PET). It is contemplated that other known methods of forming the body 18 can be employed, including, but not limited to, casting, rotational molding, thermoforming, pressure forming, compression molding, and injection molding. The body 18 also can have at least one notch 18a (See, e.g.,
Bottom Seal.
In various embodiments, the cartridge 14 includes a multi-layer, heat-sealable film, also referred to as a bottom seal 26. The bottom seal 26 forms, in part, the bottom surface of the cartridge 14, as depicted in
The bottom seal 26 has significantly improved physical characteristics and therefore provides improved cartridge performance such as precision and accuracy. For example, the fluidic channels 15 are also formed in part and sealed by the bottom seal 26. In particular, the bottom seal 26 encloses at least one volumetric fluidic channel 15 and forms a known, measurable volume. It is undesirable for the volume to change during the manufacturing of the disposable cartridge 14. Due to the properties of the film materials used to make the bottom seal 26, highly accurate fluidic volumetric channels can be formed. The separate steps taken to form the fluidic channels 15 are recommended to satisfy the tightly controlled volume requirements of each fluidic channel 15 and ensures the level of high accuracy desired for this formation process.
Additionally, the multiple layers that comprise the bottom seal 26 are specifically selected film materials that can be taken to a manufacturer for lamination or joining of the layers and/or die cutting. The selection includes materials that will melt at a temperature below that of the melting temperature of the body 18 material. The bottom seal 26 can also bond or join to the cartridge body 18 surface with high seal strength such that the enclosed fluidic channels 15 are sufficiently sealed so as to withstand high pressures or high vacuum levels.
The bottom seal 26 can be cut to various sizes as necessary during assembly. It is desirable to have the bottom seal 26 cut to a size and shape that covers and seals the fluidic channels 15 while not extending beyond the edges of the body 18 to avoid overhang which may interfere with cartridge motion during processing of the diagnostic system 10. The size and shape of the diameter of the bottom seal 26 can be configured to satisfy individual manufacturing and design requirements and are not meant to be limited by the description of the embodiments described herein. Having a bottom seal 26 that does not extend all the way to the edges of the body 18 also allows the snap fit features 20 of the cover 16 to properly engage the body 18.
In certain embodiments, the bottom seal 26 can be constructed from a combination of a thermal adhesive layer and a support layer. The thermal adhesive layer can be directly coated, formed or joined onto the support layer. Using a heat seal process, the thermal adhesive layer is able to join and seal the support layer to the cartridge body 18 to enclose the fluidic channels 15. The thermal adhesive layer thickness is sufficiently thin such that during heat sealing, melt from the thermal adhesive layer does not substantially flow into the fluidic channels and cause unwanted volumetric changes. In particular, flow of melt, i.e., flash, may cause unwanted volumetric changes to the fluidic channels, which can be avoided with a low thickness of the thermal adhesive layer.
The heat seal temperature is a characteristic of the thermal adhesive material of the thermal adhesive layer, and is advantageously lower than the melting point or glass transition temperature of the body 18 material being sealed. For example, in certain embodiments, the heat seal temperature of an exemplary thermal adhesive material can be 113° C., which is a temperature significantly lower than the glass transition temperature of the cyclic olefin copolymer, i.e., 136° C., used for injection molding the body 18. If the heat seal temperature is substantially the same or greater than the melting point or glass transition temperature of the body 18, then during heat sealing, the structure of the fluidic channels 15 may distort due to melting of the body 18 material. Any distortion to the fluidic channels 15 can change the volume which is undesirable. Thus, it is desirable that the fluidic channels 15 maintain the volumetric integrity with which each was designed.
The thermal adhesive processing temperature can be adapted to suit the desired manufacturing design, for example, by selecting different materials for the formation of the thermal adhesive layer depending on the type of material used for the body 18. Examples of suitable materials for the thermal adhesive layer include, but are not limited to, copolymers of ethylene and vinyl acetate (EVA), EVA emulsions (polyvinyl acetate copolymers based on vinyl acetate and plasticized with vinyl acetate ethylene, vinyl acetate ethylene (VAE) emulsions, vinyl acetate ethylene copolymer (VAE), copolymer adhesive, ethylene methacrylic acid copolymer (EMAA), ethylene acrylic acid copolymer, polyolefin copolymer, ethylene copolymer, propylene copolymer, polyvinyl chloride based thermoplastic resin, polyvinylidene chloride based thermoplastic resin, acrylate and styrene acrylate based thermoplastic resin, acrylate/polyolefin based thermoplastic resin, styrene copolymer based thermoplastic resin, polyester based thermoplastic resin, heat seal lacquer, or other similar materials.
The thermal adhesive layers are designed to be as thin as possible to conserve space within the overall cartridge 14 design without sacrificing effectiveness of the cartridge 14 design. In general, the thermal adhesive layers can have a thickness of less than about 1.5 mil. For example, the thermal adhesive layers can have a thickness ranging from about 0.2 mil to 1.2 mil, about 0.3 mil to about 1.0 mil, about 0.4 mil to about 0.8 mil, or about 0.5 mil to about 0.6 mil. It is contemplated that the thermal adhesive layers can have a thickness of about 1.2 mil, about 1.0 mil, about 0.8 mil, about 0.6 mil, about 0.5 mil, about 0.4 mil, about 0.3 mil, or about 0.2 mil, or any thickness in between these values and less than about 1.5 mil.
Typically, the thermal adhesive layer is thin and thus a support layer is necessary to provide sufficient stiffness, rigidity, high flexural modulus, and re-enforcement to the bottom seal 26. The support layer adds stiffness to the thin thermal adhesive layer such that the enclosed fluidic channels 15 have a flat channel surface. As a consequence, the volumes of the fluidic channels are precise and accurate across many cartridges. The support layer can be made of a material that does not melt, deflect or substantially deform during the heat sealing process. For example, the support layer can be made of polyethylene terephthalate (PET), polyvinyl chloride (PVC), cyclic olefin copolymer (COC), polyvinylidene chloride (PVDC), polystyrene, polycarbonate (PC), poly(methyl methacrylate) (PMMA), polysulfone, acrylonitrile butadiene styrene (ABS), or other similar materials. It is desirable to use materials for the support layer that are sufficiently stiff and provide high flatness on both surfaces of the combined layers. For example, in certain embodiments, the support and stiffness of the overall bottom seal 26 is derived from the support layer with PET being an example. The use of PET is also advantageous because of the characteristic dimensional stability, high flatness, and high parallelism between surfaces.
The support layer is designed to be as thin as possible to conserve space within the overall cartridge 14 design without sacrificing effectiveness of the cartridge 14 design. In general, the support layer will be thicker than the thermal adhesive layer to provide sufficient support and stiffness to the bottom seal 26. Accordingly, the support layers can have a thickness of less than about 5.0 mil. For example, the support layer can have a thickness ranging from about 4.5 mil to about 5.0 mil, from about 4.0 mil to about 4.5 mil, from about 3.0 mil to about 4.0 mil, or from about 2.5 mil to about 3.0 mil or any thickness therebetween. It is contemplated that the support layer can have a thickness of about 5.0 mil, about 4.5 mil, about 4.0 mil, about 3.7 mil, about 3.5 mil, about 3.0 mil, or about 2.5 mil.
When the thermal adhesive and support layers are combined, it is important to have smooth surfaces of the combined layers to ensure that the volume of the fluidic channels 15 is not affected by abnormalities in the surface of the bottom seal 26. It is also desirable to use materials that are dimensionally stable (low shrinkage) and have high parallelism between surfaces. Such materials should also be chemically compatible with clinical laboratory specimens, such as blood or plasma.
In certain embodiments, the bottom seal 26 can include an additional tie layer. The tie layer facilitates the adhesion of the thermal adhesive layer to the support layer. In certain embodiments, for example, the PSA layer serves to tie layers together, such as the thermal adhesive layer and the support layer. The tie layer can enable dissimilar materials for the thermal adhesive layer and support layer to be used and joined. The tie layer is advantageously thin, and does not melt or deform during the heat seal process. Examples of suitable materials for the tie layer include but are not limited to pressure sensitive adhesive (PSA), polyolefin resins, anhydride modified polyolefin, double side adhesive tapes, or similar materials.
The tie layer is designed to be as thin as possible to conserve space within the overall cartridge 14 design without sacrificing effectiveness of the cartridge 14 design. In general, the tie layers can have a thickness of less than about 1.5 mil. For example, the tie layers can have a thickness ranging from about 0.2 mil to 1.2 mil, about 0.3 mil to about 1.0 mil, about 0.4 mil to about 0.8 mil, or about 0.5 mil to about 0.6 mil. It is contemplated that the tie layers can have a thickness of about 1.2 mil, about 1.0 mil, about 0.8 mil, about 0.6 mil, about 0.5 mil, about 0.4 mil, about 0.3 mil, or about 0.2 mil, or any thickness in between these values and less than about 1.5 mil.
The materials chosen for the thermal adhesive layer, the support layer, and the tie layer may be optically transparent or optically opaque. When used, the optically transparent materials can facilitate the functions of the diagnostic system such as, for example, the use of optical sensors within the diagnostic instrument to meter appropriate divisions of fluids within the fluidic channels. The materials chosen for the thermal adhesive layer, the support layer, and the tie layer may be sufficiently thin to have low thermal resistance. The bottom seal 26 can have a total thickness which is the sum of the individual layers. Additionally, the materials chosen for the bottom seal 26 layers may bond or join to the device surface with high seal strength such that the enclosed fluidic channels are sufficiently sealed so as to withstand high pressures or high vacuum levels.
In some embodiments, the bottom seal 26 can be comprised of materials that are bondable to plastics commonly used for injection molding, including a cyclic olefin copolymer (COC). It is contemplated that when other materials are used for the injection molding of the cartridge body 18, then the thermal adhesive layer material would be altered as well. In particular, the thermal adhesive layer material composition depends on the composition of the substrate or cartridge body 18, so it is desired to have a thermal adhesive layer with a lower melting point than the body 18. Examples of suitable combinations of thermal adhesive layers with different materials for the body include, but are not limited to, the following pairs.
It contemplated that more than one of each layer may be used to construct the bottom seal 26 depending on the materials selected for each layer and the desired properties and thickness of the bottom seal 26. For example, a bottom seal construction may include alternating layers of thermal adhesive layers and tie layers on each side of a support layer.
An embodiment of a bottom seal 26 can be constructed from a thermal adhesive layer comprising a copolymer adhesive with a thickness of about 0.6 mil, a support layer comprising PET with a thickness of about 3.0 mil and a tie layer comprising pressure sensitive adhesive (PSA), with a thickness of about 1.2 mil. Such an example of a bottom seal 26 is able to seal fluidic channels 15 of the body 18 of a cartridge 14, formed by injection molding of a cyclic olefin copolymer with a glass transition temperature of 136° C., such as, for example, TOPAS® 5013.
In another embodiment, the bottom seal 26 can be constructed from two layers joined by lamination with a total thickness of about 5.4 mil, which is the sum of the layers. A thermal adhesive layer can be Transilwrap Trans-Kote® PET/MR Laminating Film with a thickness of about 1.2 mil. A support layer can be Adhesive Research ARCare 7843 with a thickness of about 4.2 mils. The low thickness of the bottom seal 26 permits the materials to be readily die cut. The materials can also be expected to have a low thermal resistance with this low thickness. The materials selected can be optically transparent.
In another embodiment, the bottom seal 26 can be constructed from two layers joined by lamination with a total thickness of about 5.4 mil, which is the sum of the layers. A first layer is constructed from the combination of a thermal adhesive layer with a thickness of about 0.6 mil and a support layer comprised of PET with a thickness of about 0.6 mil. A second layer is comprised of the tie layer made from single-sided PSA tape, e.g., composed of a 1.2 mil adhesive layer and a 3.0 mil PET support layer. The face of the single-sided tape opposite the pressure sensitive adhesive is very smooth. The PSA layer serves to tie the first layer to the second layer. The low thickness of the bottom seal 26 permits the materials to be readily die cut. The materials can also be expected to have a low thermal resistance with this low thickness. The materials selected can be optically transparent.
Top Seal.
The cartridge 14 includes a top seal 28, as depicted in
The top seal is comprised of a barrier layer and a laminating element.
The top seal can be joined to the cartridge body using a laminating element such as heat seal coating, pressure sensitive adhesive (PSA), pressure sensitive adhesive tape, thermal adhesive, transfer tape, transfer adhesive, double-sided tape, tie layer, adhesive film, or similar materials.
The top seal 28 can be die-cut or otherwise configured to have a size and shape that fits and covers only the liquid and dry reagent holding portions of the body 18 so that there is no overhanging material to interfere with cartridge performance, for example, as shown in
The top seal 28 can be made from high barrier materials that will reduce or prevent evaporation of the stored liquids. It is desirable for the top seal 28 to have a very low moisture vapor transmission rate (MVTR). For example, a material that has an MTVR that is at least two times (2×) lower than the material used to form the cartridge body 18 will not greatly contribute to any water loss from the liquid being sealed by the top seal 28. Suitable materials for the top seal 28 include, but are not limited to, aluminum foil, aluminum alloy foils, metal alloy foils, high MVTR films, high barrier films, COC films, ACLAR® films (a type of fluorinated-chlorinated resins), films made of fluorinated-chlorinated resins, duplex films, triplex films, WinCare DF10HJ712A (a Universal Sealing Blister Foil from the company WinPak).
Septum Seal.
The septum seal 30 is joined to the top face of the top seal 28 using pressure sensitive adhesive, heat sealing, bonding, or lamination. The septum seal 30 is a multi-layer film structure that is designed to connect fluidic elements between the cartridge 14 and the diagnostic device 12 using a probe. For example, the septum seal 30 can be used to establish and switch fluidic connections between the cartridge and fluidic control elements, such as a pump, a tubing assembly or fluidic pathway, and at least one probe of a diagnostic instrument. The septum seal 30 is also a multi-layer film structure that is designed to connect cartridge fluidic elements to the atmosphere using a probe. The septum seal 30 can also serve as a top seal to seal liquid filled wells or reservoirs located on the cartridge 14. The septum seal 30 can also serve as a means to clean the probe free of liquids and solids such as salts by squeegee action.
The septum seal 30 can be constructed of multiple layers including, for example, at least one septum layer 31, at least one laminating element 32, and at least one support layer 33. The septum seal 30 can have various combinations of these layers all joined together to form the multi-layer film structure. The layers can be combined to form different combinations of layers before forming the completed septum seal 30 as well as shown in
The septum layer 31 is a thin partition, film, membrane or similar structure which is pierceable, reversibly stretchable, elastic, reversibly compressible, re-sealing, self-sealing, prevents the exchange of fluids and gases, seals against a probe, and is re-addressable by a probe at the same location. The septum layer 31 has one or more probe addressable locations (shown as holes in the layers in
The septum layer 31 also can be made of a material that has a hardness of less than or equal to 110 Durometer (Shore A). The septum layer 31 can have a plurality of holes 31a, in at least one row, cut out of the layer in a predetermined pattern that can correspond to the other layers of the septum seal 30, as well as the holes 24 in the cartridge cover 16, all of which correlate to the points of contact from the probes of the diagnostic instrument 12 during operation.
The septum layer 31 can have varying thicknesses depending on the materials used for each of the layers within a given septum seal 30. For example, the septum layer can have a thickness of less than or equal to 1/10 inch, less than or equal to ⅛ inch or less than or equal to ⅙ inch.
The support layer 33 is a film, sheet, foil or similar material which reduces stretch and tension of septum layer, adds rigidity to overall structure, adds stiffness to overall structure, re-enforces overall structure, has high flexural modulus, reduces elongation of the septum layer, and is puncturable. In particular, the support layer 33 can prevent the septum layer 31 from breaking and stretching when pierced by a probe, for example. Examples of suitable materials for the support layer 33 include, but are not limited to, metals such as, aluminum, aluminum alloys, metal alloys, foils, rigid films, plastics sheeting, polytetrafluoroethylene, polyvinyl chloride, polyester, and polymers thereof. In an exemplary embodiment, the support layer 33 can be made from aluminum foil.
The support layer 33 can have varying thicknesses depending on the materials used for each of the layers within a given septum seal 30. For example, the support layer can have a thickness of less than or equal to 7 mils, less than or equal to 6 mils, less than or equal to 5 mils, less than or equal to 4 mils, less than or equal to 3 mils, less than or equal to 2 mils, or less than or equal to 1 mil. The support layer 33 can have a plurality of holes, in at least one row, cut out of the layer in a predetermined pattern that can correspond to the other layers of the septum seal 30, as well as the holes 24 in the cartridge cover 16, all of which correlate to the points of contact from the probes of the diagnostic device during operation.
The purpose of the support layer 33 is to facilitate the piercing of the septum layer 31 by a probe of the diagnostic instrument. The support layer 33 adds stiffness to the underside of the septum layer 31 for the purposes of limiting the stretch of the elastic septum layer 31 during probe entry or withdrawal. Unwanted stretching of the septum layer 31 can cause significant pressure transients (positive pressure or vacuum) within the fluidic channels of the cartridge 14. Such instances induce unintended or variable fluid motions within the channels 15 which disrupt or alter the normal positions of the fluid samples.
The laminating element 32, underneath the septum layer in
The laminating element 32 can have a plurality of holes, in at least one row, cut out of the layer in a predetermined pattern that can correspond to the other layers of the septum seal 30, as well as the holes 24 in the cartridge cover 16, all of which correlate to the points of contact from the probes of the diagnostic device during operation. It is contemplated that where more than one laminating element is used in the septum seal 30, the two laminating elements can be different materials. It is further contemplated that where more than one laminating element is used in the septum seal 30, the two laminating elements can be the same materials.
In certain embodiments, the septum seal 30 is comprised of a septum layer, a laminating element, a support layer, and a second laminating element.
In certain embodiments, the septum seal 30 is comprised of a septum layer and a double-sided pressure sensitive adhesive tape with carrier. The double sided pressure sensitive adhesive tape with carrier is comprised of a laminating element, a support layer, and a second laminating element. For example, the carrier within the double-sided pressure sensitive adhesive tape is a support layer, and the two adhesive layers within the double-sided pressure sensitive adhesive tape are laminating elements.
In certain embodiments, the septum seal 30 is comprised of a septum layer, a laminating element, and a top seal. The top seal is comprised of a support layer and a laminating element. For example, the barrier layer of the top seal is a support layer.
In certain embodiments, the septum seal 30 is an element of a closed fluidic pathway. In certain embodiments, the diagnostic system 10 employs a closed fluidic pathway between the diagnostic instrument 12 and the cartridge 14. The closed fluidic pathway provides a pathway where a sample and necessary reagents are withdrawn from the cartridge 14 using a substantially single direction of flow which returns used reagents and other waste materials back to the cartridge 14.
The septum seal 30 is designed to be addressable by a probe in one or more locations during operation of the diagnostic system. In some certain embodiments, the septum seal 30 can have a plurality of probe entry sites (formed from and found on each individual layer of the septum seal 30, as described above). These entry probe sites can be located above various internal fluidic channels, wells, fluidic elements, and reservoirs and can be arranged in a plurality of patterns according to cartridge configuration and design.
The septum seal 30 is designed to form fluidic connections between cartridge 14 and diagnostic instrument 12 when a probe pierces the septum seal 30. As used herein, to pierce is to penetrate through, or make a through hole, or to cut through, or to tear though the septum layer such that the probe is seal by the septum layer, and then self-seals or reseals when probe is removed. A pierced site is re-usable. The septum seal 30 can form a secure fluid or air passageway between the instrument 12 and cartridge 14 using a probe 128 (see
The septum seal 30 is designed to connect cartridge fluidic elements to atmosphere or ambient by puncture. As used herein, to puncture is to perforate or to make a through hole in the support layer where the hole is irreversibly formed or permanently opened using a probe. Some of these sites may act as vents, which allow ingress of atmospheric air if under vacuum or allow egress of air if under pressure. Some of these sites allow a probe to address a layer beneath the septum seal 30 without piercing the septum layer 31. There can be at least one, at least two, or a plurality of vents and they can be arranged in various configurations according to a predetermined probe pattern of the corresponding diagnostic instrument. For example, vent configurations can be varied on each layer of the septum seal 30 depending on the configuration of the cartridge and the motion path of the probes.
As described above, the individual layers of the multi-layer septum seal 30 can be pre-formed into separate layers before being combined into the septum seal. Each of the pre-formed layers can be made from materials that can be sized and formed by conventional die cutting or laser cutting methods. The patterning of the probe sites and vents of the septum seal 30 may be accomplished using conventional die cutting or laser cutting methods. Construction of the septum seal 30 may be accomplished using a conventional rotary press.
In another embodiment, the septum layer 31 can be made of 0.031 inch thick silicone rubber with hardness of 30 Durometer (Shore A). The septum layer 31 can have 13 vents to enable ingress or egress of atmospheric air. The diameter of the vents is greater than the diameter of the probe. For proper operation, the septum layer 31 as part of the septum seal 30 is not tensioned or stretched. Unwanted tensioning of the septum layer 31 may result in the pierced site not re-sealing or not self-sealing after probe withdrawal.
In still another embodiment, a support layer 33 can be joined to the septum layer 31 using a laminating element 32. The laminating element 32 can be a double-sided pressure sensitive tape such as Dielectric Polymers NT-1020. The laminating element 32 has through holes for each probe entry location so as to avoid adhesive contact with the probe 128. The diameter of the through holes is greater than the diameter of the probe 128. The laminating element 32 forms a tight seal between the septum layer 31 and support layer 33. The laminating element 32 has high peal strength to silicone rubber, and therefore the silicone rubber does not require surface modification such as corona or plasma treatment. The support layer 33 can be made from 2 mil thick aluminum foil. The support layer 33 has 34 through holes which enable the probe to address layers and features under the septum seal 30. The diameter of the through holes is greater than the diameter of the probe. The support layer 33 is joined to the cartridge 14 with a second laminating element 32. The second laminating element 32 can be a double sided pressure sensitive tape such as Dielectric Polymers NT-1020. The laminating element 32 has through holes for each probe entry location so as to avoid adhesive from contacting the probe. The diameter of the through holes is greater than the diameter of the probe. The laminating element 32 forms a tight seal between the support layer 33 and the cartridge 14. In this embodiment, the laminating elements 32 have the same through hole pattern. The register of possible probe entry locations fall along two lines due to the two probe axes of motion of the diagnostic instrument used in this embodiment.
It is contemplated that the register of possible probe entry locations can fall along one line or along two lines or more lines depending on the configuration of the diagnostic instrument 12 and the number of probes incorporated for use in the diagnostic instrument 12. Thus, it is contemplated that more or fewer lines of register sites may be used according to the design and function of the cartridge 14 and the diagnostic instrument 12 with which it functions.
Blood Collection Tube Mount.
In various embodiments, the cartridge body 18 is designed to accommodate the mounting of an industry standard blood collection tube (i.e., VACUTAINER®), or similar blood collection tube 40, which can connect to a fluidic pathway of the diagnostic system. The configuration of the blood collection tube mount 34 as described herein promotes the extraction of a majority of the blood contained within the blood collection tube 40 ensuring that the blood is accessible for extraction from the tube and processing while maintaining a low profile within the instrument and/or disposable device. In
The blood collection tube mount 34 is designed to facilitate a connection of the standard blood collection tube to a fluidic pathway(s), such as, for example, of a diagnostic instrument. The blood collection tube mount 34 is designed to allow the extraction of a majority of the blood within the blood collection tube 40. This design provides a low profile combination of the blood tube positioning to maintain minimal vertical space used in the overall cartridge design.
In certain embodiments, the blood tube mounting system or tube mount 34 can be configured to hold a blood collection tube 40 to increase blood extraction from the tube. For example, in certain embodiments, the blood tube mounting system 34 has an angle sufficient to facilitate blood extraction from the tube 40, wherein the angle can range from about less than 90° to about 0° from the horizontal. In other embodiments, the angle can range from about 45° to 0° from the horizontal. In other embodiments, the angle can range from less than 90° to about 45°, from about 45° to about 0°, from about 30° to about 0°, from about 20° to about 0°, from about 10° to about 0°, from about 7° to about 0°, from about 45° to about 20°, from about 45° to about 15°, from about 45° to about 10°, from about 35° to about 15°, from about 35° to about 10°, from about 35° to about 5°, from about 25° to about 15°, from about 25° to about 10°, from about 25° to about 5°, from about 15° to about 10°, from about 15° to about 5°, from about 10° to about 5°, from about 10° to about 7°, or from about 7° to about 5°, or from about 5° to about 0° from the horizontal. In still other embodiments, the angle can be about 45°, about 30°, about 25°, about 20°, about 15°, about 10°, about 8°, about 7°, about 6°, about 5°, about 0° from the horizontal. By way of a non-limiting example, the position at 7° can minimize the special profile of the blood tube-cartridge arrangement, preserving space in the diagnostic instrument 12 and cartridge 14.
This design configuration also can be adapted or designed to accommodate different device and instrument configurations depending on use, function and manufacturing needs and costs. This configuration can be advantageous over existing designs which have a blood tube arranged at an angle of less than 90° but that still may require tipping or additional maneuvering to get the blood out, resulting in excess dead volume due to the larger angle from the horizon (e.g., the higher the angle from the horizon, the more dead volume in the blood tube).
The blood collection tube mount 34 may further be configured to hold a blood collection tube 40 at a desired angle using ribs or other support structures 38 which constrain the tube axially along the desired angle. Certain features may be incorporated into the blood collection tube mount 34 to prevent or inhibit removal of a blood collection tube 40 after insertion into the blood collection tube mount 34, such as, for example, a shroud or tang (not depicted) may be molded in the cartridge cover 16 that inhibits gripping the blood tube 40.
In certain embodiments, the blood collection tube mount 34 can be configured to provide an indication to the user that the blood collection tube 40 is properly seated into the blood collection tube mount 34. For example, a wall 37 of the framework 36 molded into the cartridge body 18 can provide a positive stop for the blood collection tube 40 as well as provide feedback to the user that the tube 40 is fully inserted. Other indications may include, for example, a user feeling a slight pop or click after reaching a designated location in the blood collection tube mount 34 or looking through a viewing window in the cartridge cover 16 for the indication. The framework 36 can also include features that can prevent, inhibit and/or deter extraction of a blood collection tube 40 after insertion onto the framework, such as a tang (not depicted).
In certain embodiments, the blood collection tube mount 34 can be configured to guide a blood collection tube 40 onto at least one needle 42 to establish fluidic communication, such as, for example, with a diagnostic instrument 12. The guide features 38 can also facilitate the piercing of the desired portion of the blood collection tube's septum 41 by physically constraining the radial motion of the tube 40. The at least one needle 42 can be mounted for insertion through the septum 41 of a blood of a blood collection tube 40, which would facilitate, establish and maintain the fluidic connections between the needle(s) 42, 43 and a diagnostic instrument 12. In some embodiments, the blood collection tube mount 34 can have a first needle 42 and a second needle 43, such as that depicted in
The mounting of the needles 42, 43 to the framework 36 can establish connections between fluidic pathways 46 molded into the framework and the fluidic channels of the needles. Alternately, the fluidic pathways may be separate items such as tubes with the needles directly or indirectly affixed thereto where the framework provides mounting for the needle/tube combinations (not depicted). The configuration of the at least one needle 42, 43 is designed to prevent or minimize undesired communication of gasses between the needles during blood extraction. The blood collection tube mount 34 can be configured to use a pressure differential between the inside of a blood collection tube 40 and fluidic pathways 46 as the means to extract blood from the blood collection tube 40.
To facilitate a secure connection, the first and second needles 42, 43 can be incorporated into the blood collection tube mount 34 by being fitted into at least one designated recess 48 per needle configured to receive one end of a needle. The first and second needles 42, 43 can be permanently attached to the framework 36 so that the exterior surface of the first and second needles 42, 43 are sealed airtight to the framework 36 by means of an adhesive, gasket or other seal, or by insert molding the needles into the framework 36. For example,
In an embodiment where two needles are present, the first needle 42 can be mounted such that its terminal end 42a is physically separated from, and not below, the terminal end 43a of the second needle 43 within the tube 40 such that air introduced into the tube to pressurize the tube does not communicate with the second needle 43 causing an unwanted reduction in the flow of blood out of the tube 40. Thus, the terminal end of the second needle 43a is not above the terminal end of the first needle 42a, as the first needle is mounted to the framework 36 on a level above that of the second needle 43. In other words, the first needle 42 protrudes outward from the framework farther than the second needle 43 protrudes from the framework 36.
In the case of a positively pressurized blood collection tube 40, the needle by which a pressure differential is established can be mounted in a position where it will not easily communicate gasses with the needle used for blood extraction assuming they are separate entities. Thus, the needle by which a pressure differential is established is mounted such that its terminal end is physically separated from, and not below, the terminal end of the needle used for blood extraction.
Alternatively, in the case of a negatively pressurized blood collection tube, the needle by through which blood is extracted can be mounted in a position where it will not easily communicate gasses with the needle used for pressure normalization assuming they are separate entities. Thus, the needle by which blood is extracted can be mounted such that its terminal end is physically separated from, and not above, the terminal end of the needle used for pressure normalization.
A lubricant 45, such as, for example, a silicone oil, poly(p-xylylene) polymers, parylene, or polyglycol, may be applied to the exterior surface of the needles 42, 43 during assembly to reduce the force needed to pierce the septum 41 of a blood collection tube 40. Needles that are pre-coated with a lubricant can also be used. The lubricant may also assist in properly seating the blood collection tube 40 on the needles 42, 43 facilitating the needles piercing the septum 41 fully and in the desired septum location.
In embodiments where the configuration includes only one needle, rotation and viewing of a blood collection tube surface is permitted for reading of data from a surface of a blood collection tube after the blood collection tube is inserted. In such an embodiment, the framework may include features that allow automated turning of the tube to permit automated reading of text or other content (for example, barcodes or patient identification labels) off the tube.
Blood Filtration Module.
For some diagnostic applications, analysis of plasma from blood is desired, for example, analysis using a diagnostics system. Plasma is typically obtained by centrifuging whole blood samples. The present disclosure provides a diagnostic system that obtains plasma from whole blood samples by using a specialized filtration module 19 (See, e.g.,
In some embodiments, the blood filtration process generally begins with whole blood that is drawn into the cartridge by a pump of the diagnostic instrument via pressurization of the blood collection tube 40 through the longer of two needles as described above. As air is forced into the blood collection tube, blood within the tube escapes through the shorter needle and travels to the blood filter 19 through a fluidic pathway formed within the cartridge body 18. A first probe of the diagnostic instrument pierces a plasma cache fill vent in order for the plasma cache (e.g., shown in
As blood flows across the filter in a single directional flow (from right to left, for example), plasma flows through the 0.6 μm pores in the filter element of the filtration module. Plasma leaves the bottom of the filtration modules and fills the plasma cache. Retentate (concentrated whole blood) passes over the filter, and is irrevocably lost into a waste area (irrevocable because aspiration from the waste area will aspirate air, not the denser retentate). After the plasma cache is full (as determined by an optical sensor on the bottom of the cartridge), the first probe pierces the pressure release location to vent the blood collection tube to atmospheric pressure. Next the cache channel vent is pierced and the plasma is sent down the cache channel for metering. After metering, the post filter cache vent is pierced to prevent additional liquid from entering the cache from the filter, which if allowed, may block atmospheric venting of the cache channel.
Metering Biological Sample.
Aliquoting a sample into multiple volumes is a typical component of clinical testing, such as when conducting a panel of assays or when conducting replicate measurements. The diagnostic system includes components of both the diagnostic instrument and cartridge that can cooperate to divide a biological sample, such as filtered plasma, into specific volume aliquots for further processing, such as with assay reagents. The method results in a reproducible system of metering that is precise, efficient, and permits the sample to remain in the cartridge during the metering. These methods and devices can eliminate the risk of aliquoting errors common with other methods such as manual pipetting and manual steps. Manual steps can be slow, costly, and prone to human error. The methods and devices of the present disclosure are applicable to nearly any type of liquid including, but not limited to, blood, plasma, and urine and in some embodiments, the sample can be from a common source.
The metering methods described herein do not require additional user input after the cartridge is introduced into the diagnostic system. Once the cartridge is introduced into the diagnostic instrument by the user, the diagnostic test cycle begins and as it proceeds it is monitored internally by the software systems of the diagnostic system. Thus, upon insertion, the diagnostic instrument first identifies the cartridge and the diagnostic test to be completed within the present cycle. The appropriate test sequence is initiated by the software and the timing, speed, and duration of all subsequent fluid motions are initiated and controlled.
An aliquoting device can be a sub-section of a diagnostic system. Other sub-sections include mechanisms for carrying out an immunoassay such as mixing, incubating, free-bound separation, and readout. The aliquoting mechanism can be directly integrated into a diagnostic system. In some embodiments, it is intended that an aliquoting mechanism uses pre-existing features of the diagnostic system such as an external fluidic system including a pump and other features that will become apparent. It is further intended that an aliquoting method, along with the other immunoassay process steps, may be automated. It is further intended that the aliquoting mechanism derives its accuracy and precision independently of the external fluidic system.
In some embodiments, an aliquot method of the presently disclosed diagnostic system can be comprised of three operations which use the features of the aliquoting device.
The aliquot method has a precision and accuracy independent of pump accuracy. In this method, a first operation can be to draw sample liquid from the sample reservoir (also referred to as plasma cache) 52 into the primary channel 54. The extent of filling the primary channel 54 is independent of pump accuracy. The second operation can be to empty the remaining sample liquid from the sample reservoir 52 into the secondary channel 55. The second operation is also independent of pump accuracy. The leftover liquid volume is the excess of sample liquid over total aliquot volume (where total aliquot volume is the aliquot volume multiplied by the number of aliquots). The final operation is to draw a segment of liquid from the sample liquid located in the primary channel 54 between receiver channels 56 into a receiver channel 56. The volume of liquid in the primary channel 54 between receiver channels 56 is the aliquot volume. This is done for each receiver channel 56 (the number of which is dependent on the cartridge design and the diagnostic test being run on the cartridge). This operation is also independent of pump accuracy. At the end of the method, all sample liquid that was contained in the sample reservoir 52 is aliquoted into each of the receiver channels 56 and the secondary channel 55.
The aliquot device 51 can accommodate any type of clinical sample such as blood, plasma or urine. In some embodiments of the aliquot device 51, the clinical sample to be aliquoted is located within a sample reservoir 52. The means for locating the sample into the reservoir 52 would be apparent to anyone skilled in the art of assay construction and can be as described herein. The sample reservoir 52 can have a volume ranging from about 125 μL to about 135 μL, about 135 μL to about 150 μL, about 150 μL to about 175 μL, and about 175 μL to about 200 μL. The sample reservoir can have a volume of about 150 μL, about 175 μL, about 200 μL, about 225 μL, or any volume therebetween. In an exemplary embodiment the sample reservoir 52 can have a volume of about 200 μL. The opening of the sample reservoir 52 is located on the top surface of the aliquot device 51 and the sample reservoir 52 is open vented to ambient.
The sample reservoir 52 can be connected to a primary channel 54. The primary channel 54 can have a volume less than the sample reservoir volume. For example, the primary channel 54 can have a volume ranging from about 125 μL to about 135 μL, about 135 μL to about 150 μL, about 150 μL to about 175 μL, and about 175 μL to less than about 200 μL. The primary channel can also have a volume of about 125 μL, about 150 μL, about 175 μL, about 200 μL, or any volume therebetween.
In an exemplary embodiment the primary channel 54 can have a volume of about 150 μL. The primary channel is connected to an end channel 59. The end channel 59 can have a volume of about 20 μL, about 25 μL, about 30 μL, or any volume therebetween. In an exemplary embodiment the end channel 59 can have a volume of about 25 μL. The end channel 59 is connected to a pump connecting port 53. Also connected to the primary channel 54 are three receiver channels 56. The volume of each receiver channel 56 is designed to be greater than the aliquot volume 58 and can be equal to about 50 μL, about 75 μL, about 100 μL, or any volume therebetween. In an exemplary embodiment each receiver channel 56 can have a volume of about 75 μL.
Also connected to the primary channel 54 is a secondary channel 55. External to the aliquot device 51 can be a sensor 62 to detect when a liquid front reaches the primary channel fill mark (not shown). The sensor 62 can be used to detect when a liquid front reaches the secondary channel fill mark (not shown). The volume of the secondary channel 55, based on the fill mark, is designed to be greater than the difference in volume between the sample reservoir 52 and primary channel 54 volume. The secondary channel 55 can have a volume ranging from about 125 μL to about 135 μL, about 135 μL to about 150 μL, about 150 μL to about 175 μL, and about 175 μL to less than about 200 μL. For example, the secondary channel can have a volume of about 125 μL, about 150 μL, about 175 μL, about 200 μL, or any volume therebetween. In an exemplary embodiment the secondary channel 55 can have a volume of about 150 μL.
The secondary channel 55 and each receiver channel 56 are connected to pump connecting ports 53. The number of pump connecting ports can vary depending on the configuration of the cartridge 14, and may range from 5 to 7 pump connecting ports. For example, in an embodiment, there may be a total of 5 pump connecting ports. The pump connecting ports 53 are normally closed. The fluidic channels, i.e., secondary channel 55, receiver channels 56, and end channel 59, are in fluidic communication with a pumping mechanism through the pump connecting ports 53. Fluid motion between the fluidic channels necessary for the aliquot method can be conducted by applying vacuum pressure from a pump (not depicted). The aliquot volume 58 can be defined as the volume between adjacent receiver channels 56. The number of aliquots can be defined as the number of receiver channels 56.
The sample volume does not require a precise or accurate fill in the sample reservoir 52 but only that its volume exceeds a minimum. For example, the minimum sample reservoir fill can be about 75 μL, about 100 μL, about 125 μL, or any volume therebetween. In an exemplary embodiment the, the minimum sample reservoir fill volume can be about 100 μL.
The second operation is emptying the remaining or leftover sample liquid from the sample reservoir 52 into the secondary channel 55. This fluid motion is driven by vacuum generated inside the secondary channel 55 due to a pump being connected to the secondary channel pump connecting port 53. During this operation, the other connecting ports are closed. The second operation is also independent of pump accuracy. When the liquid front of the sample reaches the secondary channel fill mark 60, the sensor 62 which addresses the aliquot device 51, communicates to the pump to stop and release from the secondary channel pump connecting port 53.
The final operation is drawing each aliquot volume into a receiver channel 56. This is conducted sequentially and three times for each of the three receiver channels 56, for example, in an embodiment with five secondary channel pump connecting ports 53. The sequence of drawing aliquot volumes into a receiving channel 56 is conducted in order and starting with the aliquot volume closest to the secondary channel 55 (e.g., from left to right in
The aliquot device 51 is adaptable by increasing or decreasing the number of aliquots accommodated on an aliquot device 51. For example, the number of aliquots can be greater than or equal to (≧1), or less than or equal to the sample volume in the sample reservoir 52 divided by the aliquot volume.
The aliquot device 51 is further adaptable by increasing or decreasing the aliquot volume deliverable within an aliquot device 51. The aliquot volume is driven by the available sample volume and the number of aliquots. For example, an aliquot volume may be less than or equal to the sample volume divided by the number of aliquots.
The aliquot device 51 is further adaptable by aliquoting the sample equally into multiple volumes. For example, the aliquot volume may be the same within an aliquot device 51.
The aliquot device 51 is further adaptable by accommodating different aliquot volumes within a single aliquot device 51. For example, there may be two or more different aliquot volumes within an aliquot device 51.
The aliquot device and method avoid using pump displacement as a mechanism which determines aliquot volume and avoid using any mechanism for aliquoting a sample where pump accuracy and precision drive/determine the accuracy and precision of the aliquoting method. The accuracy and precision of the aliquoting method is independent of pump accuracy and precision.
Reagent Handling Stations (RHS). The diagnostic system provides a unique liquid storage well, or a reagent handling station (RHS), which can be used for storage of reagents, as a probe wash station, and as a waste containment area on a cartridge during processing of a diagnostic test. The RHS 64 of
In general, a RHS 64 is made of a reservoir 65 that has low dead volume and is comprised of walls with low moisture vapor transmission rate (MVTR) due to the thickness and material of the walls. The walls of the reservoir 65 can be formed from the cartridge body and be of the same material such as Cyclic Olefin Copolymer (COC). Liquid drawn from this reservoir washes the first probe's exterior and serves as a source of carrier fluid for the transport of reagents to the instrument detection cell. The RHS reservoir 65 has a depth greater than the length of a probe 128 of the diagnostic instrument 12, which allows for the reduction in the dead volume. The size and shape of the RHS reservoir 65 can vary as long as it can be sealed, e.g., with a foil seal, and there is enough space in the top to vent the liquids to air prior to aspiration.
The depth of the containment pocket (including the probe pocket) must be shorter than the sample probe. In particular, a pocket 66 with a specific geometry is present in the bottom of a RHS reservoir 65 which provides the reduced dead volume by facilitating contact with increased fluids by the probe 128 within the reservoir pocket area 66. For example, the RHS reservoir 65 can have a depth of about 0.40 in., about 0.45 in., or about 0.50 in., or depths therebetween, including, about 0.42 in., about 0.43 in., about 0.46 in., about 0.47 in., about 0.48 in. The RHS reservoir 65 can have a total volume of about 1.5 mL, about 1.7 mL, about 2.0 mL, or total volumes therebetween, such as about 1.6 mL and 1.9 mL. In an exemplary embodiment, a 0.0625 in. diameter and a 0.041 in. deep well at the bottom of the RHS reservoir 65 enables a more complete removal of liquids from the well (minimizing dead volume).
The RHS 64 further comprises a multi-layered foil heat seal, i.e., top seal 28, such as that previously described herein. The top seal 28 can be heat sealed to the top of the RHS reservoir 65. The top seal 28 functions to help with cleaning the exterior of the probe as it traverses the seal, acting similar to a squeegee. The seal facilitates probe cleaning and can reduce carryover between readings during operation. The seal further facilitates the introduction of air to liquid transitions during liquid draws. The seal is comprised of a specially developed foil seal designed to heat seal to thin walls of COC plastic in order to keep the moisture vapor transmission rate low and maintain a minimum size of the device. The thin walls and the seal also help to maintain thermal uniformity. The top seal 28 can be made of a foil seal such as Winpak LTD-WINCARE DF10HJ712A Heat Sealing Foil.
The area of a RHS reservoir 65 is large enough to allow for at least one probe entry site, for example two probes from a diagnostic instrument 12. In an exemplary embodiment, the RHS reservoir 65 diameter was selected to allow for a ±0.013 in. positioning error of the sample probe before it strikes the edge of the probe pocket 66. The probe entry sites 68, 69 serve to vent the reservoirs, and therefore the cartridge, to the atmosphere, which is important for the fluidic functions of the cartridge. Evaporation can be minimized through both the seal and pierced holes in the seal. The cartridge can withstand changes in atmospheric pressure when sealed.
The pocket 66 is sufficiently large enough to allow access of the probe and allow for puncturing a separate hole 69 for venting to atmosphere. Vent 69 requires an air gap beneath the seal to prevent liquid from exiting through the opening. The aspiration location 68 can be under a septum to reduce salt accumulation on the probe 128. The septum, i.e., septum seal 30, can provide squeegee cleaning action on the sample probe when removed from the aspiration location 68 up through the septum. In some embodiments, a septum is a 0.032 inch thick rubber material (e.g., 30 durometer Silicone).
When a probe 128 from a diagnostic instrument enters the RHS reservoir 65 and draws the reagents into the probe 128, the reagents can act as a cleaning agent. The fluid motion along the probe draws particles on both the outside and inside surfaces of the probe up into the diagnostic instrument and eventually to a waste containment area. The introduction of air bubbles by moving the diagnostic instrument probe up and down in the vented reagent handling station 64 allows the introduction of small bubbles. These bubbles aid in the cleaning of the probe surfaces by increasing the scrubbing action along the surfaces. This cleaning decreases the carryover between reads.
In certain embodiments, liquids drawn into the diagnostic instrument are returned to the cartridge before the run is complete. To minimize the size of the cartridge, the RHS 64 can be reused as a waste compartment for the previously processed liquids. Capillary action keeps the waste liquid in the cartridge even upon inversion of the device despite the probe-created holes in the foil or plastic. For example, a 0.0355″ hole has a capillary pressure equivalent to 0.71 inches of water, which is 1.5× the head pressure from the deepest waste cavity (0.46″).
In an embodiment, the volume of the RHS reservoir 65 is 1.7 mL to the top and the fill volume is 1.3 mL. The fill volume should be close to the usable volume. However, the fill volume should not match the total volume as the foil will not properly seal if wet. The 0.062 in. diameter probe pocket 66 enables liquid to drain to the probe 128. In some embodiments, the cartridge 14 material is a Cyclic Olefin Copolymer (COC) because of the low Moisture Vapor Transmission Rate (MVTR). For example the MVTR for Polyplastics TOPAS® 5013, a COC, is 0.00193 g/100 int/day. With such a low MVTR, while some liquid may evaporate during storage, less than 1.2% of liquid reagent will evaporate, in some embodiments. This 0.016 mL evaporation is negligible when considering the fill capacity of the RHS well.
While the present discussion is largely focused on the use of the RHS 64 with assays, it is not meant to be limiting and is only one example for which this RHS 64 can be used. For example, the RHS 64 can have utility in any long term liquid storage on any plastic disposable device.
Mixing and Pre-Incubation Sample Preparation Method.
The diagnostic system provides methods for rehydrating lyophilized reagent pellets, e.g., with a patient sample, while minimizing foaming, producing homogenously mixed sample before an incubation, and positioning the homogeneously mixed sample to an incubation zone similarly located for each assay replicate in order to improve the accuracy and the precision of a clinical assay.
The rehydrating lyophilized pellets contain magnetic beads. Rehydrating a lyophilized pellet with a patient sample causes foaming in the mixture. The foam generated while rehydrating lyophilized pellets can trap the magnetic beads. The foam generated is more variable than the liquid with regard to moving in a fluidic channel. A greater yet unknown amount of foam may be left on the walls of the fluidic channel. This can result in more, and an inconsistent number of, beads to also be left on the walls, and cannot reach the incubation chamber. This can in turn cause an unknown amount of beads from being properly incubated with a patient sample, which can result in inaccurate and imprecise measurements.
In certain embodiments, the mixing and preparation method can minimize foam during the rehydration of the lyophilized pellets, which minimizes the variability between assay replicates as well as between cartridges, thus improving the precision. This can be accomplished during rehydration of lyophilized pellets by detecting the leading edge of a sample with an optical sensor 62 (
Certain embodiments provide a cartridge that can have different geometries in a cartridge assay replicates (CAR) 70 (
In one embodiment, the active mix well 72 bottom can have a diameter of 0.045 in., the bead capture zone 74 can have a height of 0.024 in., and the wash channel can have a height of 0.036 in. To ensure that the sample is incubated at the identical location in each channel, the leading edge location of the sample is verified with the optical sensor 62 before positioning the sample to the incubation zone 76.
Tables 1-3 below show a software playlist that can be used for each objective with a detailed description of each process given below each Table. The CAR components mentioned in the description below are identified in
Step 1 commands a pump to aspirate a sample toward the active mix well until an optical sensor detects the leading edge of the sample (an air to liquid transition detected by a sensor measurement difference sited by the fifth parameter “−100” when the sensor measurement changes by −100 my or more, indicates that air to liquid transition has taken place). Step 2 moves the sample further ensuring that the optical sensor is aligned with the sample fully and not just the transition, which enables to measure the correct reference signal for its next detection (liquid to air). Step 3 commands the pump to aspirate the sample toward and into the active mix well rehydrating the lyophilized reagents pellets with the sample until the optical sensor detects the trailing edge of the sample. Notice that Step 3 uses a flow rate of 5 μL/sec whereas the Line 1 utilizes a flow rate of 10 μL/sec. Step 3 introduces the sample slowly into the active mix well in order to minimize foaming while rehydrating the lyophilized reagent pellets. Step 4 ensures that the optical sensor is aligned with air that follows the sample (channel that had been wet by the sample, but has air now) and takes the correct reference signal for its next detection.
Step 1 commands the pump to dispense a sample into a wash channel such that the trailing edge of the sample moves past the bead capture zone. Step 2 commands the pump to aspirate and to move the sample across the bead capture zone back into the active mix well. Notice that Step 1 moves the sample at a flow rate of 10 μL/sec whereas Step 2 moves the sample at a flow rate of 40 μL/sec. A slower flow rate while moving the sample from the active mix well into the wash channel (Step 1) avoids leaving beads on the active mix well wall. A faster flow rate while moving the sample back into the active mix well promotes a proper mixing.
During the mix cycle, a sample moves between an active mix well 72 and a wash channel 78 across a bead capture zone 74 and experiences changes in the cross sectional area, e.g., from 0.0016 in2 to 0.0011 in2 between the wash channel and the bead capture zone and from 0.0011 in2 to 0.0016 in2 between the bead capture zone and the mix well bottom.
Step 3 and Step 4 repeat the mixing cycle. Step 5 and Step 6 repeat the mixing cycle but differ in that it aspirates the sample back into the active mix well at 10 μL/sec, instead of 40 μL/sec, in order to bring back some of the beads that might have been left in the wash channel during the 40 μL/sec aspiration of previous two mixing cycles.
Step 1 commands a pump to dispense until an optical sensor detects the leading edge of a sample. Step 2 positions the sample to the incubation zone. Notice that a slow flow rate (5 μL/sec) avoids leaving beads on the active mix well wall.
Method for Detecting Air to Liquid and Liquid to Air Transitions in a Fluidic Channel.
The diagnostic system provides methods for detecting the transition of air to liquid and liquid to air boundaries in a fluidic channel, such as for a diagnostic cartridge. Certain embodiments provide a method for detecting air to liquid (and liquid to air) boundaries in a fluidic channel, comprising using an optical sensor (can be the same optical sensor 62 now used as a reflective object sensor); emitting light onto a detection spot of a channel with an infrared emitting diode; detecting the reflective light with a phototransistor, wherein the emitter and detector are side by side housed.
Some embodiments also provide a method for measuring liquid volumes (and air volumes) in a fluidic channel, comprising recording the time when an air liquid boundary and liquid air boundary passes a detection spot; calculating the volume of liquid (or air) passing the detection spot based on the flow rate (pump rate, volume velocity) and time.
Some embodiments provide methods for detecting the transition of air liquid and liquid air boundaries in a fluidic sealed channel. Some embodiments use an optical reflective object sensor 62 (in
The sensor 62 can be an optical sensor and may use an infrared emitting diode and a NPN (NPN is one of the two types of bipolar transistors, consisting of a layer of P-doped semiconductor (the “base”) between two N-doped layers) silicon phototransistor, as depicted in
An illustration of a cross section of a fluidic channel is depicted in
In a diagnostic system, a cartridge may have multiple channels to conduct similar diagnostics sample preparations or tests. In some embodiments, only one sensor 62 is used or is necessary, and a cartridge motion mechanism 122 (See, e.g.,
While a fluidic channel is being monitored by a sensor, fluid motion can be activated by a pump 140 connected to tubing 138a, 138b, 138c and connected to a probe 128a, 128b (e.g., hollow needle that can make fluidic connection with the fluidic channels inside a cartridge), depicted in
The sensor 62 located at the bottom of the cartridge 14 positioned at the optimal distance away from the cartridge 14, monitoring the contents of the cartridge, can be used for verification of volume, detection of presence of undesired air bubbles, verification of the location of the sample, detecting undesired leaks and/or undesired clogs in the fluidic channels. A typical output from such a system monitoring the fluidic channel where a volume of liquid is passed is shown in
In some embodiments, the ability to detect air and liquid boundaries with proper software is used to detect air and clogs in a fluidic system, the presence of leaks and clogs will produce inaccurate results, proper diagnostics will enable the system not to generate any results, rather than wrong results.
The methods of the present disclosure allow for verification of volume, detection of presence of undesired air bubbles, verification of the location of the sample, detecting undesired leaks and/or undesired clogs in the fluidic channels which can be used as a diagnostics mechanism by software to detect undesired behavior with the system that could produce erroneous results if not otherwise detected. Detection of the air to liquid and liquid to air transition can also be used for volume measurement of a liquid volume (more likely a sample that contains the antigen for detection, which the volume is important in measuring precise and accurate concentration) by the use of software.
The liquid/air detection methods are simple and inexpensive methods to detect liquid to air and air to liquid transaction in a sealed fluidic channel. Fluidic volumes can be computed and verified by properly detecting the edges of a liquid volume, e.g., which is being moved by a pump at a constant flow rate. Air bubbles can be identified in otherwise expected liquid volumes, and then can invalidate results obtained from such channel, e.g., if the air bubble is large enough to have compromised the integrity of the volume.
Bead Washing. After the aliquoted sample is mixed with the lyophilized (otherwise dry) reagents, and incubation of the mixture has begun, the steps of capturing the beads within the mixture and washing them for detection occurs next. In particular, the diagnostic system provides methods for washing off blood or plasma and free label from beads in a cartridge bead based assay with no human intervention. This includes, but is not limited to, methods for washing off a sample (e.g., patient's blood, plasma or bodily fluids) and free label from beads that have a specific antigen and label bound to them.
These methods can increase sensitivity and accuracy by decreasing the noise in the background, as well as not allowing the rest of the matrix (bodily fluids) from exiting the cartridge (which contains the sample and reagents) and entering and possibly contaminating the instrument (performing the detection). The methods achieve a highly effective wash method, by capturing the beads to be washed in a magnetic field, and then passing a liquid-and-air combination over the beads, in a fluidic channel using a very small amount of wash liquid.
In certain embodiments, the methods include steps to remove a patient's blood or plasma from the beads, for example, so that when the beads enter the diagnostic instrument for detection, there are no detectable remnants of a specific patient sample contaminating the diagnostic instrument. In certain other embodiments, the methods include steps to remove the matrix containing free label that has not bound to beads, for example, so that they do not contain relevant information to the measurement, in order to reduce the background signal generated during the detection of the label that has bound to beads. Some embodiments wash the patient's sample off from the beads, after the binding reaction is completed, while using a very small amount of wash fluid.
Other embodiments use a cartridge-based system where all reagents are housed on the cartridge (eliminating the need to use an externally connected reagent apparatus to a diagnostic instrument). It is advantageous to keep the volumes to be stored on the cartridge small, in a manner such that the resulting footprints for cartridges and diagnostic instruments are small, such as, for example, in the case of an diagnostic instrument for a point of care setting. One advantage of some of these embodiments is that it eliminates human intervention and it allows for a more precise and accurate measurement hence better diagnostics, by reducing the measurement background.
Typically, human intervention is used to wash beads that have been used to form immunoassays. Beads in a fluidic sample of measurement external to the “detection instrument” have been washed with buffer in order to remove the free label and other possible contaminants from the beads. These human intervention methods require the transfer of the beads from and to the diagnostic instrument. To minimize human intervention and allow a more precise and accurate measurement, the present disclosure provides a cartridge-based system, in which the sample is washed within the cartridge before isolating the washed sample into the system for measurement.
An exemplary apparatus used for a method disclosed for the present disclosure may comprise a cartridge that contains a well that is sealed by a septum where the fluidic system connects to it via a probe. The apparatus can also include a fluidic channel that connects the sealed well to a vented opening, as well as a reservoir for buffer solution. The cartridge can have a thin film bottom sealing the fluidic channels as well as allowing the necessary magnetic field to be applied to capture the beads in the fluid and hold on to them while they are being washed. The apparatus can also include a fluidic system that contains an inlet, an outlet, a detection module, a pump, and tubing connecting these components that can generate fluidic motion in the fluidic channels in a cartridge, as well as aspirate and dispense fluids and air in and out of the cartridge.
In certain embodiments, the wash methods can include a sequence of operations in order to capture and wash the beads effectively. For example, the magnet can be raised as the incubated sample, which may contain a patient's blood or plasma mixed and incubated with reagents that contain the beads, flows due to a fluidic system, across a portion of the channel where the magnet makes contact. Using a pump, the reagent pack can be aspirated (consecutive chunks or segments of liquid buffer and air) into the fluidic system (tube) via the probe of the diagnostic instrument. The composition of the pack can influence the cleaning quality. The amount of liquid buffer needed to wash the beads has been determined by the diagnostic system, accomplished by having air and liquid combination in a reagent pack. A liquid air boundary has shown to be very effective in brushing the surface of the beads.
Using the pump and the fluidic system, the reagent pack is able to flow over into the fluidic channel that is sealed at the probe end and vented on the other side of the patient sample, while the beads remain held to the bottom of the cartridge by the magnet. The above sequence can push the sample away, so that the beads can sit in the clean buffer. The magnet then can be lowered and a series of push-pull action is applied in the pump (aspirate, dispense) that moves the fluid with the beads back and forth inside the cartridge across the bead capture zone to re-suspend, into clean buffer, beads that had been pulled to the bottom of the cartridge. This provides the washed beads in the clean buffer that now can be aspirated into the fluidic system to be analyzed in the detection module.
Preventing Reuse of a Single Use Device.
Some embodiments of the diagnostic instrument provide methods to prevent reuse of a single use clinical device (i.e., a cartridge), for example, by detecting fluid flow characteristics that differ between a used and an unused device. This contributes to the prevention of false results incurred by inappropriate use of a used single use clinical device and also prevents the time loss incurred by processing an inappropriate test.
In certain embodiments, detection of a previously used single use clinical device is accomplished by means of a pump used to generate a pressure and a pressure sensor to detect either a vented path that is vented in a used clinical device but not in an unused clinical device or an unvented path that would be unvented in a used clinical device but not in an unused clinical device. This test allows a diagnostic instrument to quickly determine the use status of a clinical device and to disallow processing of a used single use clinical device.
Some embodiments provide a means of detecting a previously used single use clinical device, including detecting a previously used single use clinical device for the purpose of preventing invalid results. Other embodiments provide a means of detecting a previously used single use clinical device by measuring pressure changes and/or a means of generating a positive or negative pressure and detecting the introduction of a previously used single use clinical device by changes in that pressure. Still other embodiments provide a means of detecting a previously used single use clinical device by use of a pump to establish or fail to establish a pressure within the used clinical device for subsequent measurement. Some embodiments provide a means of detecting a previously used single use clinical device by placing a pressure transducer within the fluidic channel that communicates with a device in order to measure a change or lack of change in an established pressure.
In certain embodiments, single use clinical devices have seals, valves, or other features that control fluidic motion to enable processing of results whose fluidic flow state is changed during use, for example, with an opened valve or a pierced foil seal. In some embodiments, when the clinical device use is completed, a fluidic pathway configuration of a new device is no longer the same, such as a pierced foil seal or a valve left closed rather than open. By introducing and detecting a pressure in a fluidic pathway that should not be sealed or by failing to introduce a pressure in a fluidic pathway that should be sealed, a used single use clinical device can be detected and rejected as not usable thus preventing invalid results from being presented.
Certain embodiments provide methods to prevent reuse of a single use clinical device, for example, (i) by means of a pressure measurement to detect changes in the device brought about during use; (ii) by means of a pressure introduced into the used device and detecting a state only present in a used device; and/or (iii) by means of a pressure transducer to detect an expected pressure introduced into the used device and detecting a state only present in a used device.
Certain embodiments, such as that depicted in
Case—1: Detecting a single use clinical device in which the test chamber is not vented 108 if the single use clinical device is used. Detection of a maintained pressure is indicative of a used single use clinical device whereas detection of a loss of pressure is indicative of an unused single use clinical device.
Case—2: Detecting a single use clinical device in which the test chamber is vented 110 if the single use clinical device is used. Detection of a maintained pressure is indicative of an unused single use clinical device whereas detection of a loss of pressure is indicative of a used single use clinical device.
Undesired reuse of a single use clinical device can be prevented by means of the detection of pressure changes and/or pressure status within the device to determine its use status. In some embodiments, a system is comprised of a pump 94 capable of pressurizing the single use clinical device to a level at which pressure level and pressure change can be detected. A pressure transducer 96 is used to monitor the pressure within the pressurized fluidic channels of the system. Typically, but not necessarily, a tube 98 is used to connect the pump 94 to a hollow needle 100, probe or fitment (hereafter called needle, but the present disclosure is not limited to a needle) in fluidic communication to both the pump 94 and the needle 100. The pressure transducer 96 may be situated anywhere within the fluidic pathway. The location of the pressure transducer 96 may be within the pump chamber 96 as long as the chamber is in fluidic communication with the tube 98 and needle 100 during detection. The needle 100 is placed in fluidic communication with a target chamber of the single use clinical device by a convenient means forming an air-tight connection to the single use clinical device. Pressure is introduced into the chamber of the single use clinical device 106 by means of the pump 94 or other controlled pressure source and then measured to determine the state of the pressure over some elapsed time.
In certain other embodiments, processing of a single use clinical device can be designed to deliberately leave the device in a fluidic state other than its unused state. A single use clinical device can be further designed to allow an air-tight fluidic connection by the needle 100 for a used single use clinical device detection. This may be in the form of a vent which is opened or closed during normal processing or may be a separate feature designed specifically for use detection reasons. If the feature is unvented 108 or closed after use, then pressurization is attempted and then measured, detection of the established pressure indicates a used single use clinical device, whereas detection of a loss of pressure indicates an unused device. If the feature is vented 110 or opened after use, then pressurization is attempted and then measured. Detection of the established pressure indicates an unused single use clinical device, whereas detection of a loss of pressure indicates a used device.
The present disclosure is not restricted to a vent and it is contemplated that any structure such as a valve, a pierced membrane, a broken feature, or activation of a material whose fluid flow properties may be readily changed would serve the same function.
Pump Storage Fluid.
A pump storage liquid prevents/inhibits the formation of solids between the piston and cylinder by, for example, not evaporating and/or by solubilizing any residual salt or solids present in the dead volume of a pump. This non-volatile liquid acts as a lubricant for the seal or tight fitting piston and cylinder set of a pump within the diagnostic instrument. Stiction is avoided because lubricant persistently fills the gap between the piston and cylinder. In this manor the pump storage liquid prevents the pump seals or tight fitting piston and cylinder set from drying out and therefore prevents freezing, seizing, or stiction.
Additionally, the present disclosure provides a pump storage liquid which enables the pump to recover from storage without wetting the seals or tight fitting piston and cylinder set. The minimum amount of pump storage liquid required to protect a pump can be very low, e.g. 1 mL. The pump storage liquid can be present in an amount ranging from about 1 mL to about 2 mL, from about 1 mL to about 1.5 mL, or from about 1.5 mL to about 2 mL. The minimum amount of pump storage liquid required to protect the pump depends on the gap volume between the piston and cylinder set. For example, a one inch diameter piston and one inch length chamber with a 2 micron gap between piston and cylinder has a gap volume of 4 μL. This is the minimum amount of pump storage liquid required to protect such pump.
The pump storage fluid can be stored on the cartridge of the diagnostic system and used at the end of the each cartridge run.
Desiccant Competition with Dry Reagents.
In the design of disposable diagnostic devices, it is desirable to have lyophilized or dried assay reagents to increase product stability at room temperature storage. It is also desirable to process the assay with a liquid buffer, not limited to but useful for rehydration, washing, or assay processing. In certain embodiments, it is advantageous to contain both the dried reagent on the same device as the liquid buffer. Protection of the dried reagent from the liquid buffer increases the stability of the assay and the shelf life of the device.
Thus, some embodiments provide an improved method for storing both dry reagents and liquid buffer on board a disposable device. This method is not limited to diagnostic devices but lends itself to the aforementioned issues as well. Some embodiments comprise a method using desiccant material used specifically to extend the shelf life of dry reagents on a disposable device that stores both liquid and dry reagents where there is a pathway connecting the dry reagents and vapors from the liquid reagents. For example, the present disclosure provides a desiccating system for a clinical device that has both stored liquids and dry reagents which is able to prevent water from interacting with the dry reagents and for which the cartridge has an open passageway from the interior location of the dry reagent to exterior where a desiccant is located.
Some embodiments can keep the dried reagents stable in the presence of liquid for a minimum of two years.
In one embodiment, the moisture vapor transfer from the liquid reagent wells on the disposable device to the exterior is sufficiently small so that the chemical concentrations of the liquid reagents aren't adversely affected by evaporation over the shelf life and so that the dry reagents on the same device are not prematurely rehydrated over the shelf life by the evaporated liquid.
By way of a prophetic example only, a cross sectional area that water vapor can diffuse through is approximately 524 mm2 and because of a 1° taper in the molded disposable, the wall thickness varies at the wells from about 0.040 in. to about 0.055 in.
A disposable device can be made from a Cyclic Olefin Copolymer, e.g., with the Trade name of TOPAS®. The moisture vapor transmission rate (MVTR) for TOPAS® grade 5013 is about 0.03 g mm/(m2 day) at 23° C. and 85% RH. Using the average wall thickness of about 0.047 in., the transfer rate is therefore [0.03 g mm/(m2 day)] {(524×10−6 m2)/(0.047×25.4 mm)=13.2 μg/day/assay.
Accordingly, it can be predicted based on the calculations above, that to achieve over a two year shelf life, a disposable device will release about 87 mg of water. The device is pouched in a foil seal and there is a path 120 through a needle that will allow the ambient (within the foil pouch) to reach the dry reagents. If this released 87 mg of water is allowed to reach the dry reagents, the shelf life of the device is shortened greatly. In order to keep the amount of evaporated water to be less than 6.6% of the DRIERITE® mass (6.6% is the maximum moisture absorption with a strong affinity), the amount of DRIERITE® has to be greater than 1.3 g. DRIERITE® desiccants are made from the naturally occurring mineral, gypsum (Calcium Sulfate), and are available in several varieties designed to solve all types of drying problems. DRIERITE® is an all-purpose drying agent for the efficient and rapid drying of air, industrial gases, refrigerants, organic liquids and solids. The smallest bag of DRIERITE® readily sold is 3 g, which is more than sufficient for the device.
DRIERITE® is sufficiently aggressive and out-competes the dry reagents for water absorption that slowly diffuse from the liquid buffer and through the plastic walls of the disposable. While DRIERITE® is described herein as an exemplary desiccant, the present disclosure is not limited to the use of DRIERITE® as the desiccant.
All publications, patents and patent applications mentioned in this specification are herein incorporated by reference in their entirety into the specification to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. Also incorporated by reference is any supplemental information that was published along with any of the aforementioned publications, patents and patent applications. For example, some journal articles are published with supplemental information that is typically available online.
Citation or discussion of a reference herein shall not be construed as an admission that such is prior art to the present disclosure.
As used herein the transitional term “comprising” is open-ended. A claim utilizing this term can contain elements in addition to those recited in such claim. Thus, for example, the claims can read on methods that also include other steps not specifically recited therein, as long as the recited elements or their equivalent are present.
For the purpose of illustrating the invention, there are depicted in the drawings certain embodiments of the invention. However, the invention is not limited to the precise arrangements and instrumentalities of embodiments depicted in the drawings.
The following examples are merely illustrative and intended to be non-limiting.
A sensor output was used to compute the volume of the liquid, by computing the time that the liquid was present and multiplying by the pump's flow rate during the fluid motion. Also, the fact that there were no interruptions in the “low” signal (e.g., remains low, does not go up to the 0.6 V level) indicated that there were no air bubbles in the fluid volume. In this example above, air and liquid boundaries happened twice, one at about time point=81 and the other at about 318 (in this example where the flow rate was 10 μL/sec, liquid volume deleted was then 318−81=237 data points where each was 10 ms, making the total volume detected 23.7 μl.
The pump continued aspirating the sample, and as soon as a liquid to air transition was detected, the software made the copy of the timer (T2), after which the pump was stopped (
The following are examples of calculations that were used to determine clogs, leaks and/or verification and when desired correction of volumes.
Vx=(T1−T0)*Fr will be compared to Va, Vx>Va will indicate a leak. If Vx>>Va may indicate a clog in between pump and the probe.
Vy=(T2−T1)*Fr will be compared to Vs to verify the accuracy of the aliquot.
This application claims priority to U.S. Provisional Application No. 61/647,272, filed May 15, 2012, and International PCT Application No. PCT/US2012/067041, filed on Nov. 29, 2012, each of which is herein incorporated by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3705100 | Blatt et al. | Dec 1972 | A |
| 4212742 | Solomon et al. | Jul 1980 | A |
| 4225410 | Pace | Sep 1980 | A |
| 4228015 | De Vries et al. | Oct 1980 | A |
| 4301412 | Hill et al. | Nov 1981 | A |
| 4301414 | Hill et al. | Nov 1981 | A |
| 4336121 | Enzer et al. | Jun 1982 | A |
| 4381775 | Nose' et al. | May 1983 | A |
| 4397725 | Enzer et al. | Aug 1983 | A |
| 4436610 | Enzer et al. | Mar 1984 | A |
| 4540492 | Kessler | Sep 1985 | A |
| 4548498 | Folestad et al. | Oct 1985 | A |
| 4631130 | Watanabe | Dec 1986 | A |
| 4675300 | Zare et al. | Jun 1987 | A |
| 4735718 | Peters | Apr 1988 | A |
| 4735776 | Yamamoto et al. | Apr 1988 | A |
| 4762594 | Guruswamy | Aug 1988 | A |
| 4786394 | Enzer et al. | Nov 1988 | A |
| 4799393 | Uffenheimer | Jan 1989 | A |
| 4820129 | Magnussen, Jr. | Apr 1989 | A |
| 4833087 | Hinckley | May 1989 | A |
| 4835477 | Polaschegg et al. | May 1989 | A |
| 4887458 | Baker et al. | Dec 1989 | A |
| 4929426 | Bodai et al. | May 1990 | A |
| 4965049 | Lillig et al. | Oct 1990 | A |
| 5023054 | Sato et al. | Jun 1991 | A |
| 5061445 | Zoski et al. | Oct 1991 | A |
| 5068088 | Hall et al. | Nov 1991 | A |
| 5074977 | Cheung et al. | Dec 1991 | A |
| 5093268 | Leventis et al. | Mar 1992 | A |
| 5096582 | Lombardi et al. | Mar 1992 | A |
| 5130254 | Collier et al. | Jul 1992 | A |
| 5139328 | Baker et al. | Aug 1992 | A |
| 5139685 | de Castro et al. | Aug 1992 | A |
| 5143084 | Macemon et al. | Sep 1992 | A |
| 5147806 | Kamin et al. | Sep 1992 | A |
| 5155039 | Chrisope et al. | Oct 1992 | A |
| 5208163 | Charlton et al. | May 1993 | A |
| 5223219 | Subramanian et al. | Jun 1993 | A |
| 5223718 | Taboada | Jun 1993 | A |
| 5238808 | Bard et al. | Aug 1993 | A |
| 5247243 | Hall et al. | Sep 1993 | A |
| 5279797 | Burns et al. | Jan 1994 | A |
| 5288646 | Lundsgaard et al. | Feb 1994 | A |
| 5296191 | Hall et al. | Mar 1994 | A |
| 5298224 | Plum | Mar 1994 | A |
| 5302348 | Cusack et al. | Apr 1994 | A |
| 5310687 | Bard et al. | May 1994 | A |
| 5316730 | Blake et al. | May 1994 | A |
| 5372946 | Cusak et al. | Dec 1994 | A |
| 5399486 | Cathey et al. | Mar 1995 | A |
| 5405510 | Betts et al. | Apr 1995 | A |
| 5416026 | Davis | May 1995 | A |
| 5453356 | Bard et al. | Sep 1995 | A |
| 5466416 | Ghaed et al. | Nov 1995 | A |
| 5487870 | McKinney et al. | Jan 1996 | A |
| 5500187 | Deoms et al. | Mar 1996 | A |
| 5504011 | Gavin et al. | Apr 1996 | A |
| 5506142 | Mahaffey et al. | Apr 1996 | A |
| 5522255 | Neel et al. | Jun 1996 | A |
| 5525518 | Lundsgaard et al. | Jun 1996 | A |
| 5527710 | Nacamulli et al. | Jun 1996 | A |
| 5534226 | Gavin et al. | Jul 1996 | A |
| 5543112 | Ghead et al. | Aug 1996 | A |
| 5558838 | Uffenheimer | Sep 1996 | A |
| 5567869 | Hauch et al. | Oct 1996 | A |
| 5575977 | McKinney et al. | Nov 1996 | A |
| 5591403 | Gavin et al. | Jan 1997 | A |
| 5591581 | Massey et al. | Jan 1997 | A |
| 5593638 | Davis | Jan 1997 | A |
| 5597910 | Gudibande et al. | Jan 1997 | A |
| 5599447 | Pearl et al. | Feb 1997 | A |
| 5601727 | Bormann et al. | Feb 1997 | A |
| 5602037 | Ostgaard et al. | Feb 1997 | A |
| 5610075 | Stahl-Rees | Mar 1997 | A |
| 5624637 | Ghaed et al. | Apr 1997 | A |
| 5627041 | Shartle | May 1997 | A |
| 5629209 | Braun, Sr. et al. | May 1997 | A |
| 5635347 | Link et al. | Jun 1997 | A |
| 5641623 | Martin | Jun 1997 | A |
| 5643713 | Liang et al. | Jul 1997 | A |
| 5653243 | Lauks et al. | Aug 1997 | A |
| 5660993 | Cathey et al. | Aug 1997 | A |
| 5665238 | Whitson et al. | Sep 1997 | A |
| 5665315 | Robert et al. | Sep 1997 | A |
| 5666967 | Lauks et al. | Sep 1997 | A |
| 5679519 | Oprandy et al. | Oct 1997 | A |
| 5686244 | Gudibande et al. | Nov 1997 | A |
| 5698406 | Cathey et al. | Dec 1997 | A |
| 5700427 | Ghaed et al. | Dec 1997 | A |
| 5705402 | Leland et al. | Jan 1998 | A |
| 5714089 | Bard et al. | Feb 1998 | A |
| 5716781 | Massey et al. | Feb 1998 | A |
| 5720922 | Ghaed et al. | Feb 1998 | A |
| 5731147 | Bard et al. | Mar 1998 | A |
| 5736404 | Yassinzadeh et al. | Apr 1998 | A |
| 5743861 | Columbus et al. | Apr 1998 | A |
| 5744367 | Talley et al. | Apr 1998 | A |
| 5746974 | Massey et al. | May 1998 | A |
| 5747666 | Willis | May 1998 | A |
| 5770459 | Massey et al. | Jun 1998 | A |
| 5779650 | Lauks et al. | Jul 1998 | A |
| 5779976 | Leland et al. | Jul 1998 | A |
| 5795543 | Poto et al. | Aug 1998 | A |
| 5798083 | Massey et al. | Aug 1998 | A |
| 5800781 | Gavin et al. | Sep 1998 | A |
| 5804400 | Martin et al. | Sep 1998 | A |
| 5821399 | Zelin | Oct 1998 | A |
| 5827481 | Bente et al. | Oct 1998 | A |
| 5846485 | Leland et al. | Dec 1998 | A |
| 5851488 | Saul et al. | Dec 1998 | A |
| RE36054 | Blake et al. | Jan 1999 | E |
| 5858676 | Yang et al. | Jan 1999 | A |
| 5882602 | Savage et al. | Mar 1999 | A |
| 5885533 | Savage et al. | Mar 1999 | A |
| 5888826 | Ostgaard et al. | Mar 1999 | A |
| 5912134 | Shartle | Jun 1999 | A |
| 5914042 | Ball et al. | Jun 1999 | A |
| 5919711 | Boyd et al. | Jul 1999 | A |
| 5922210 | Brody et al. | Jul 1999 | A |
| 5935779 | Massey et al. | Aug 1999 | A |
| 5945344 | Hayes et al. | Aug 1999 | A |
| 5962218 | Leland et al. | Oct 1999 | A |
| 5968329 | Anderson et al. | Oct 1999 | A |
| 5980830 | Savage et al. | Nov 1999 | A |
| 5981294 | Blatt et al. | Nov 1999 | A |
| 5983734 | Mathur et al. | Nov 1999 | A |
| 6016712 | Warden et al. | Jan 2000 | A |
| 6048687 | Kenten et al. | Apr 2000 | A |
| 6057151 | Greenwood et al. | May 2000 | A |
| 6069014 | Schrier et al. | May 2000 | A |
| 6078782 | Leland et al. | Jun 2000 | A |
| 6082185 | Saaski | Jul 2000 | A |
| 6087476 | Kenten et al. | Jul 2000 | A |
| 6096500 | Oprandy et al. | Aug 2000 | A |
| 6099760 | Jameison et al. | Aug 2000 | A |
| 6112888 | Sauro et al. | Sep 2000 | A |
| 6120986 | Martin | Sep 2000 | A |
| 6132648 | Zhang et al. | Oct 2000 | A |
| 6132955 | Talley et al. | Oct 2000 | A |
| 6140138 | Bard et al. | Oct 2000 | A |
| 6146838 | Williams et al. | Nov 2000 | A |
| 6165708 | Liang et al. | Dec 2000 | A |
| 6165729 | Leland et al. | Dec 2000 | A |
| 6174709 | Kenten et al. | Jan 2001 | B1 |
| 6187267 | Taylor et al. | Feb 2001 | B1 |
| 6193864 | Leader et al. | Feb 2001 | B1 |
| 6200531 | Liljestrand et al. | Mar 2001 | B1 |
| 6214552 | Heroux et al. | Apr 2001 | B1 |
| 6217744 | Crosby | Apr 2001 | B1 |
| 6271041 | Leland et al. | Aug 2001 | B1 |
| 6274087 | Preston et al. | Aug 2001 | B1 |
| 6312591 | Vassarotti et al. | Nov 2001 | B1 |
| 6312896 | Heroux et al. | Nov 2001 | B1 |
| 6316180 | Martin | Nov 2001 | B1 |
| 6316607 | Massey et al. | Nov 2001 | B1 |
| 6319670 | Sigal et al. | Nov 2001 | B1 |
| 6319719 | Bhullar et al. | Nov 2001 | B1 |
| 6325973 | Leland et al. | Dec 2001 | B1 |
| 6379969 | Mauze et al. | Apr 2002 | B1 |
| 6387290 | Brody et al. | May 2002 | B1 |
| 6391541 | Petersen et al. | May 2002 | B1 |
| 6398956 | Coville et al. | Jun 2002 | B1 |
| 6403384 | Lea | Jun 2002 | B1 |
| 6406672 | Buhllar et al. | Jun 2002 | B1 |
| 6432720 | Chow | Aug 2002 | B2 |
| 6438498 | Opalsky et al. | Aug 2002 | B1 |
| 6440725 | Pourahmadi et al. | Aug 2002 | B1 |
| 6448091 | Massey et al. | Sep 2002 | B1 |
| 6451225 | Leland et al. | Sep 2002 | B1 |
| 6468741 | Massey et al. | Oct 2002 | B1 |
| 6475372 | Ohara et al. | Nov 2002 | B1 |
| 6479233 | Bard et al. | Nov 2002 | B1 |
| 6488896 | Weigl et al. | Dec 2002 | B2 |
| 6495104 | Unno et al. | Dec 2002 | B1 |
| 6517777 | Liljestrand et al. | Feb 2003 | B2 |
| 6524513 | Pearl et al. | Feb 2003 | B1 |
| 6524865 | Martin et al. | Feb 2003 | B1 |
| 6534137 | Vadhar | Mar 2003 | B1 |
| 6537501 | Holl et al. | Mar 2003 | B1 |
| 6554788 | Hunley et al. | Apr 2003 | B1 |
| 6559096 | Smith et al. | May 2003 | B1 |
| 6613280 | Myrick et al. | Sep 2003 | B2 |
| 6613286 | Braunn, Sr. et al. | Sep 2003 | B2 |
| 6613583 | Richter et al. | Sep 2003 | B1 |
| 6635418 | Heroux et al. | Oct 2003 | B2 |
| 6656428 | Clark et al. | Dec 2003 | B1 |
| 6664104 | Pourahmadi et al. | Dec 2003 | B2 |
| 6676902 | Baugh et al. | Jan 2004 | B2 |
| 6699718 | Bruegger | Mar 2004 | B1 |
| 6702986 | Leland et al. | Mar 2004 | B1 |
| 6740240 | Coville et al. | May 2004 | B2 |
| 6748332 | Chen | Jun 2004 | B2 |
| 6750053 | Widrig Opalsky et al. | Jun 2004 | B1 |
| D494589 | Liljestrand et al. | Aug 2004 | S |
| 6776965 | Wyzgol et al. | Aug 2004 | B2 |
| 6783736 | Taylor et al. | Aug 2004 | B1 |
| 6794877 | Blomberg et al. | Sep 2004 | B2 |
| 6808939 | Sigal et al. | Oct 2004 | B2 |
| D499035 | Cook et al. | Nov 2004 | S |
| 6818185 | Petersen et al. | Nov 2004 | B1 |
| 6824663 | Boone | Nov 2004 | B1 |
| 6831733 | Pettersson et al. | Dec 2004 | B2 |
| 6846629 | Sigal et al. | Jan 2005 | B2 |
| 6852284 | Holl et al. | Feb 2005 | B1 |
| 6852502 | Martin | Feb 2005 | B1 |
| 6861259 | Columbus | Mar 2005 | B2 |
| 6866823 | Wardlaw | Mar 2005 | B2 |
| 6869570 | Wardlaw | Mar 2005 | B2 |
| 6878540 | Pourahmadi et al. | Apr 2005 | B2 |
| 6880384 | Hvidtfeldt et al. | Apr 2005 | B2 |
| 6881536 | Shah et al. | Apr 2005 | B1 |
| 6881541 | Petersen et al. | Apr 2005 | B2 |
| 6881589 | Leland et al. | Apr 2005 | B1 |
| 6887693 | McMillan et al. | May 2005 | B2 |
| 6893879 | Petersen et al. | May 2005 | B2 |
| 6919173 | Tsionsky et al. | Jul 2005 | B2 |
| 6926834 | Coville et al. | Aug 2005 | B2 |
| 6929953 | Wardlaw | Aug 2005 | B1 |
| 6949377 | Ho | Sep 2005 | B2 |
| 6969450 | Taniike et al. | Nov 2005 | B2 |
| 6977722 | Wohlstadter et al. | Dec 2005 | B2 |
| D515220 | Miller et al. | Feb 2006 | S |
| 7004184 | Handique et al. | Feb 2006 | B2 |
| 7008796 | Wohlstadter et al. | Mar 2006 | B2 |
| 7011794 | Kagan et al. | Mar 2006 | B2 |
| 7018353 | Hunley et al. | Mar 2006 | B2 |
| 7036917 | Müller-Chorus et al. | May 2006 | B2 |
| 7041206 | Gephart et al. | May 2006 | B2 |
| 7061595 | Cabuz et al. | Jun 2006 | B2 |
| 7111503 | Brumboiu et al. | Sep 2006 | B2 |
| 7115421 | Grzeda et al. | Oct 2006 | B2 |
| 7135547 | Gengrinovitch | Nov 2006 | B2 |
| 7205116 | Salamone et al. | Apr 2007 | B2 |
| 7235213 | Mpock et al. | Jun 2007 | B2 |
| 7238246 | Peters et al. | Jul 2007 | B2 |
| 7247488 | Ghai et al. | Jul 2007 | B2 |
| 7277166 | Padmanabhan et al. | Oct 2007 | B2 |
| 7282179 | Iwaki et al. | Oct 2007 | B2 |
| 7285425 | Shareef et al. | Oct 2007 | B2 |
| 7288195 | Coville et al. | Oct 2007 | B2 |
| 7299081 | Mace et al. | Nov 2007 | B2 |
| 7306727 | Perreault | Dec 2007 | B2 |
| 7314711 | Richter et al. | Jan 2008 | B2 |
| 7329538 | Wainwright et al. | Feb 2008 | B2 |
| 7335339 | Brendtsson | Feb 2008 | B2 |
| 7378270 | Azarnia et al. | May 2008 | B2 |
| 7384409 | Fischer et al. | Jun 2008 | B2 |
| 7399637 | Wright et al. | Jul 2008 | B2 |
| 7419821 | Davis et al. | Sep 2008 | B2 |
| 7422903 | Conlon et al. | Sep 2008 | B2 |
| 7422905 | Clague et al. | Sep 2008 | B2 |
| 7438853 | Zen et al. | Oct 2008 | B2 |
| 7439017 | Heroux et al. | Oct 2008 | B2 |
| 7439069 | Nippoldt et al. | Oct 2008 | B2 |
| 7471394 | Padmanabhan et al. | Dec 2008 | B2 |
| 7481787 | Gable et al. | Jan 2009 | B2 |
| 7485153 | Padmanabhan et al. | Feb 2009 | B2 |
| 7494819 | Bahatt et al. | Feb 2009 | B2 |
| 7497997 | Glezer et al. | Mar 2009 | B2 |
| 7521247 | De Haan | Apr 2009 | B2 |
| 7523649 | Corey et al. | Apr 2009 | B2 |
| 7547384 | Keenan | Jun 2009 | B2 |
| 7553448 | Kumar et al. | Jun 2009 | B2 |
| 7553453 | Gu et al. | Jun 2009 | B2 |
| 7569346 | Petersen et al. | Aug 2009 | B2 |
| 7569393 | Sin | Aug 2009 | B2 |
| 7595169 | Swaim et al. | Sep 2009 | B2 |
| 7604777 | Columbus | Oct 2009 | B2 |
| 7608042 | Goldberger et al. | Oct 2009 | B2 |
| 7630063 | Padmanabhan et al. | Dec 2009 | B2 |
| 7641856 | Padmanabhan et al. | Jan 2010 | B2 |
| 7666355 | Alavie et al. | Feb 2010 | B2 |
| 7682511 | de Los Reyes et al. | Mar 2010 | B2 |
| 7682788 | Sigal et al. | Mar 2010 | B2 |
| 7723099 | Miller et al. | May 2010 | B2 |
| 7736901 | Opalsky et al. | Jun 2010 | B2 |
| 7767794 | Salamone et al. | Aug 2010 | B2 |
| 7771658 | Larsen | Aug 2010 | B2 |
| 7776583 | Billadeau et al. | Aug 2010 | B2 |
| 7781226 | McDevitt et al. | Aug 2010 | B2 |
| 7816124 | Samsoondar | Oct 2010 | B2 |
| 7820102 | Myrick et al. | Oct 2010 | B2 |
| 7822510 | Paik et al. | Oct 2010 | B2 |
| RE41946 | Anderson et al. | Nov 2010 | E |
| 7824925 | Wohlstadter et al. | Nov 2010 | B2 |
| 7833746 | Berndtsson et al. | Nov 2010 | B2 |
| 7838631 | Yamashita et al. | Nov 2010 | B2 |
| 7859670 | Kim et al. | Dec 2010 | B2 |
| 7887750 | Blatt et al. | Feb 2011 | B2 |
| 7888125 | Gibbons et al. | Feb 2011 | B2 |
| 7901629 | Calatzis et al. | Mar 2011 | B2 |
| 7911617 | Padmanabhan et al. | Mar 2011 | B2 |
| 7914994 | Petersen et al. | Mar 2011 | B2 |
| 7923256 | Widrig Opalsky et al. | Apr 2011 | B2 |
| 7928718 | Larsen | Apr 2011 | B2 |
| 7932098 | Childers et al. | Apr 2011 | B2 |
| 7939021 | Smith et al. | May 2011 | B2 |
| 7952069 | Shiokawa et al. | May 2011 | B2 |
| 7977106 | Widrig Opalsky et al. | Jul 2011 | B2 |
| 7978329 | Padmanabhan et al. | Jul 2011 | B2 |
| 7981362 | Glezer et al. | Jul 2011 | B2 |
| 7985589 | Garner et al. | Jul 2011 | B2 |
| 8003060 | Cracauer et al. | Aug 2011 | B2 |
| 8007670 | Connors, Jr. | Aug 2011 | B2 |
| 8008034 | Gibbons et al. | Aug 2011 | B2 |
| 8012744 | Gibbons et al. | Sep 2011 | B2 |
| 8012745 | Glezer et al. | Sep 2011 | B2 |
| 8017382 | Davis et al. | Sep 2011 | B2 |
| 8021873 | Johnson et al. | Sep 2011 | B2 |
| 8028566 | Larsen | Oct 2011 | B2 |
| 8034296 | Cox et al. | Oct 2011 | B2 |
| 8046175 | Kuo et al. | Oct 2011 | B2 |
| 8071051 | Padmanabhan et al. | Dec 2011 | B2 |
| 8101404 | Samsoondar | Jan 2012 | B2 |
| 8101431 | McDevitt et al. | Jan 2012 | B2 |
| 8105783 | Handique | Jan 2012 | B2 |
| 8105849 | McDevitt et al. | Jan 2012 | B2 |
| 8137626 | Maltezos et al. | Mar 2012 | B2 |
| 8236555 | Stromgren et al. | Aug 2012 | B2 |
| 8273566 | Billadeau et al. | Sep 2012 | B2 |
| 8343526 | Billadeau et al. | Jan 2013 | B2 |
| 8372353 | Lee et al. | Feb 2013 | B2 |
| 8394595 | Jung et al. | Mar 2013 | B2 |
| 8394608 | Ririe et al. | Mar 2013 | B2 |
| 8481901 | Bedingham et al. | Jul 2013 | B2 |
| 8585279 | Rida | Nov 2013 | B2 |
| 8623638 | Solomon | Jan 2014 | B2 |
| 8747779 | Sprague et al. | Jun 2014 | B2 |
| 8772017 | Battrell et al. | Jul 2014 | B2 |
| 8778665 | Gibbons et al. | Jul 2014 | B2 |
| 8846310 | Johnson et al. | Sep 2014 | B2 |
| 8870446 | Rida | Oct 2014 | B2 |
| 8895295 | Ririe et al. | Nov 2014 | B2 |
| 20020019060 | Petersen et al. | Feb 2002 | A1 |
| 20020098116 | Sugaya et al. | Jul 2002 | A1 |
| 20020143297 | Francavilla et al. | Oct 2002 | A1 |
| 20020155033 | Strand et al. | Oct 2002 | A1 |
| 20030029254 | Hvidtfeldt et al. | Feb 2003 | A1 |
| 20030035758 | Buechler et al. | Feb 2003 | A1 |
| 20030052054 | Pearl et al. | Mar 2003 | A1 |
| 20030073089 | Mauze et al. | Apr 2003 | A1 |
| 20030185707 | Iwaki et al. | Oct 2003 | A1 |
| 20030224523 | Thornberg et al. | Dec 2003 | A1 |
| 20040035792 | Rauch et al. | Feb 2004 | A1 |
| 20040086872 | Childers et al. | May 2004 | A1 |
| 20040096368 | Davis et al. | May 2004 | A1 |
| 20040176704 | Stevens et al. | Sep 2004 | A1 |
| 20040228765 | Witty et al. | Nov 2004 | A1 |
| 20040228766 | Witty et al. | Nov 2004 | A1 |
| 20040248284 | Van Beuningen | Dec 2004 | A1 |
| 20040259268 | Jacobs et al. | Dec 2004 | A1 |
| 20050014279 | Nguyen et al. | Jan 2005 | A1 |
| 20050042137 | Petersen et al. | Feb 2005 | A1 |
| 20050074900 | Morgan et al. | Apr 2005 | A1 |
| 20050181443 | Sun et al. | Aug 2005 | A1 |
| 20050220668 | Coville | Oct 2005 | A1 |
| 20050227370 | Ramel et al. | Oct 2005 | A1 |
| 20050245844 | Mace et al. | Nov 2005 | A1 |
| 20050250173 | Davis et al. | Nov 2005 | A1 |
| 20060094028 | Danna et al. | May 2006 | A1 |
| 20060165558 | Witty et al. | Jul 2006 | A1 |
| 20060177347 | Larsen et al. | Aug 2006 | A1 |
| 20060218010 | Michon et al. | Sep 2006 | A1 |
| 20060228259 | Samsoondar | Oct 2006 | A1 |
| 20060257854 | McDevitt et al. | Nov 2006 | A1 |
| 20060257941 | McDevitt et al. | Nov 2006 | A1 |
| 20060257991 | McDevitt et al. | Nov 2006 | A1 |
| 20060263818 | Scherer et al. | Nov 2006 | A1 |
| 20060275841 | Blankfard et al. | Dec 2006 | A1 |
| 20070003434 | Padmanabhan et al. | Jan 2007 | A1 |
| 20070009386 | Padmanabhan et al. | Jan 2007 | A1 |
| 20070031283 | Davis et al. | Feb 2007 | A1 |
| 20070036026 | Laibinis et al. | Feb 2007 | A1 |
| 20070116600 | Kochar et al. | May 2007 | A1 |
| 20070166195 | Padmanabhan et al. | Jul 2007 | A1 |
| 20070166196 | Bardell et al. | Jul 2007 | A1 |
| 20070166725 | McBride et al. | Jul 2007 | A1 |
| 20070172388 | Padmanabhan et al. | Jul 2007 | A1 |
| 20070178514 | Van Beuningen | Aug 2007 | A1 |
| 20070178521 | Sakaino et al. | Aug 2007 | A1 |
| 20070248497 | Robillot | Oct 2007 | A1 |
| 20070292941 | Handique et al. | Dec 2007 | A1 |
| 20080021296 | Creaven | Jan 2008 | A1 |
| 20080025872 | Dykes et al. | Jan 2008 | A1 |
| 20080057572 | Petersen et al. | Mar 2008 | A1 |
| 20080131322 | Kheiri et al. | Jun 2008 | A1 |
| 20080149840 | Handique et al. | Jun 2008 | A1 |
| 20080153078 | Braman et al. | Jun 2008 | A1 |
| 20080188732 | Mace et al. | Aug 2008 | A1 |
| 20080227219 | Gamez | Sep 2008 | A1 |
| 20080311002 | Kirby et al. | Dec 2008 | A1 |
| 20090018411 | Mace et al. | Jan 2009 | A1 |
| 20090047713 | Handique | Feb 2009 | A1 |
| 20090065357 | Glezer et al. | Mar 2009 | A1 |
| 20090081078 | Caramuta | Mar 2009 | A1 |
| 20090098541 | Southern et al. | Apr 2009 | A1 |
| 20090130658 | Barlag et al. | May 2009 | A1 |
| 20090130719 | Handique | May 2009 | A1 |
| 20090148882 | Goldstein | Jun 2009 | A1 |
| 20090151792 | Noda | Jun 2009 | A1 |
| 20090181864 | Nguyen et al. | Jul 2009 | A1 |
| 20090215072 | McDevitt et al. | Aug 2009 | A1 |
| 20090221059 | Williams et al. | Sep 2009 | A1 |
| 20090246076 | Kumar et al. | Oct 2009 | A1 |
| 20090253130 | Yoo | Oct 2009 | A1 |
| 20090311736 | Ciotti et al. | Dec 2009 | A1 |
| 20090325276 | Battrell et al. | Dec 2009 | A1 |
| 20100029011 | Sin | Feb 2010 | A1 |
| 20100081144 | Holmes et al. | Apr 2010 | A1 |
| 20100112723 | Battrell et al. | May 2010 | A1 |
| 20100117666 | Wada et al. | May 2010 | A1 |
| 20100158756 | Taylor et al. | Jun 2010 | A1 |
| 20100159556 | Rida | Jun 2010 | A1 |
| 20100173394 | Colston, Jr. et al. | Jul 2010 | A1 |
| 20100197522 | Liu et al. | Aug 2010 | A1 |
| 20100203521 | Klapperich et al. | Aug 2010 | A1 |
| 20100203550 | Miller et al. | Aug 2010 | A1 |
| 20100227412 | Cerda | Sep 2010 | A1 |
| 20100240022 | McNeely | Sep 2010 | A1 |
| 20100261292 | Glezer et al. | Oct 2010 | A1 |
| 20100262304 | Gonnella et al. | Oct 2010 | A1 |
| 20100282609 | Pollack et al. | Nov 2010 | A1 |
| 20100285578 | Selden et al. | Nov 2010 | A1 |
| 20100290952 | Koike et al. | Nov 2010 | A1 |
| 20100291588 | McDevitt et al. | Nov 2010 | A1 |
| 20100303722 | Jin et al. | Dec 2010 | A1 |
| 20110008908 | Biesbrouck | Jan 2011 | A1 |
| 20110016691 | Alden et al. | Jan 2011 | A1 |
| 20110039298 | Berndtsson et al. | Feb 2011 | A1 |
| 20110067489 | Haberstroh et al. | Mar 2011 | A1 |
| 20110091357 | Blatt et al. | Apr 2011 | A1 |
| 20110100101 | Zenhausern et al. | May 2011 | A1 |
| 20110143378 | Putnam | Jun 2011 | A1 |
| 20110171754 | Redmond et al. | Jul 2011 | A1 |
| 20110192218 | Miyamura et al. | Aug 2011 | A1 |
| 20110192219 | Miyamura et al. | Aug 2011 | A1 |
| 20110194977 | Miyamura et al. | Aug 2011 | A1 |
| 20110195490 | Kang et al. | Aug 2011 | A1 |
| 20110195495 | Selden et al. | Aug 2011 | A1 |
| 20110201909 | Emery et al. | Aug 2011 | A1 |
| 20110203924 | Wohlstadter et al. | Aug 2011 | A1 |
| 20110259091 | Laubscher et al. | Oct 2011 | A1 |
| 20110269159 | Campbell et al. | Nov 2011 | A1 |
| 20110269222 | Miller et al. | Nov 2011 | A1 |
| 20110290669 | Davis et al. | Dec 2011 | A1 |
| 20110294224 | Liu | Dec 2011 | A1 |
| 20110312553 | Silverbrook et al. | Dec 2011 | A1 |
| 20110312661 | Silverbrook et al. | Dec 2011 | A1 |
| 20110312742 | Silverbrook et al. | Dec 2011 | A1 |
| 20110318774 | Larsen | Dec 2011 | A1 |
| 20120003730 | Padmanabhan et al. | Jan 2012 | A1 |
| 20120009667 | Peterson et al. | Jan 2012 | A1 |
| 20120034624 | Miller et al. | Feb 2012 | A1 |
| 20120034645 | Billadeau et al. | Feb 2012 | A1 |
| 20120043202 | Miyamura et al. | Feb 2012 | A1 |
| 20120045375 | Miyamura et al. | Feb 2012 | A1 |
| 20120051972 | Joseph | Mar 2012 | A1 |
| 20120053335 | Liu et al. | Mar 2012 | A1 |
| 20120115213 | Hofstadler et al. | May 2012 | A1 |
| 20120141337 | Maltezos et al. | Jun 2012 | A1 |
| 20120177537 | Aota et al. | Jul 2012 | A1 |
| 20120190128 | Nikbakht et al. | Jul 2012 | A1 |
| 20120252138 | Sasso, Jr. et al. | Oct 2012 | A1 |
| 20130137172 | Ririe et al. | May 2013 | A1 |
| 20140017709 | Lowe et al. | Jan 2014 | A1 |
| 20140186935 | Yoo | Jul 2014 | A1 |
| 20140329301 | Handique | Nov 2014 | A1 |
| Number | Date | Country |
|---|---|---|
| 486059 | Jan 1997 | EP |
| 1489303 | Dec 2004 | EP |
| 2007905 | Dec 2008 | EP |
| 2281631 | Feb 2011 | EP |
| 2419217 | Feb 2012 | EP |
| 2112293 | Jul 1983 | GB |
| 2010-237050 | Oct 2010 | JP |
| 8706706 | Nov 1987 | WO |
| 9005302 | May 1990 | WO |
| 9419683 | Sep 1994 | WO |
| 9419684 | Sep 1994 | WO |
| 9508644 | Mar 1995 | WO |
| 9621154 | Jul 1996 | WO |
| 9635697 | Nov 1996 | WO |
| 9635812 | Nov 1996 | WO |
| 9641177 | Dec 1996 | WO |
| 9915694 | Apr 1999 | WO |
| 2005095954 | Oct 2005 | WO |
| 2007002579 | Jan 2007 | WO |
| 2007005626 | Jan 2007 | WO |
| 2011027092 | Mar 2011 | WO |
| 2011113569 | Sep 2011 | WO |
| 2012024543 | Feb 2012 | WO |
| 2012058632 | May 2012 | WO |
| 2012136695 | Oct 2012 | WO |
| 2013082273 | Jun 2013 | WO |
| 2013136115 | Sep 2013 | WO |
| 2013173524 | Nov 2013 | WO |
| 2013173525 | Nov 2013 | WO |
| 2014043388 | Mar 2014 | WO |
| Entry |
|---|
| Ascoli, et al., “Drug Binding to Human Serum Albumin: Abridged Review of Results Obtained with High-Performance Liquid Chromatography and Circular Dichroism”, Chirality, vol. 18:667-679 (2006). |
| Bertino, et al., “5-Fluorouracil Drug Management: Pharmacokinetics and Pharmacogenomics Workshop Meeting Summary; Orlando, Florida; Jan. 2007”, Clinical Colorectal Cancer, vol. 6(6):407-422 (2007). |
| Bertucci, et al., “The Binding of 5-fluorouracil to Native and Modified Human Serum Albumin: UV, CD, and 1H and 19F NMR Investigation”, Journal of Pharmaceutical and Biomedical Analysis, vol. 13:1087-1093 (1995). |
| Beumer, et al., “A Rapid Nanoparticle Immunoassay to Quantitate 5-Fluorouracil (5-FU) in Plasma”, ASCO GI 2008 Meeting (Poster). |
| Crowley, et al., “Isolation of Plasma from Whole Blood Using Planar Microfilters for Lab-on-a-Chip Applications”, Lab Chip, vol. 5(9):922-929 (2005). |
| Jaffrin, M.Y. (1995). Biological Flows. M.Y. Jaffrin and Colin Caro (Eds.). Plenum Press, New York, pp. 199-226. |
| Joseph, et al., “Evaluation of Alternatives to Warfarin as Probes for Sudlow Site I of Human Serum Albumin Characterization by High-Performance Affinity Chromatography”, J. Chromatogr. A., vol. 1216(16):3492-3500 (2009). |
| Lukas, et al. , “Binding of Digitoxin and Some Related Cardenolides to Human Plasma Proteins”, The Journal of Clinical Investigation, vol. 48:1041-1053 (1969). |
| Madsen, et al., “Cooperative Interaction of Warfarin and Phenylbutazone with Human Serum Albumin”, Biochemical Pharmacology, vol. 30(11):1169-1173 (1981). |
| Means, et al. (1982). Modification of Proteins: Food, Nutritional, and Pharmacological Aspects. Robert E. Feeny and John R. Whitaker (Eds.). American Chemical Society. pp. 325-346. |
| Olympus UK Ltd—Diagnostics Laboratory News Directory, http://www.labnewsdirectory.co.uk/company/Olympus-UK-Ltd-Diagnostics/2232, (Oct. 1, 2009). |
| Peters, T., Jr., “Serum Albumin”, Adv. Protein Chem., vol. 37:161-246 (1985). |
| Peyrin, et al., “Characterization of Solute Binding at Human Serum Albumin Site II and its Geometry Using a Biochromatographic Approach”, Biophysical Journal, vol. 77:1206-1212 (1999). |
| Saif, et al. “Pharmacokinetically Guided Doe Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes”, J. Natl. Cancer Inst., vol. 101:1543-1552 (2009). |
| Salamone, et al., “Novel Monoclonal Antibodies for Measuring 5-Fluorouracil Concentrations in Biological Fluids”, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition); vol. 24(18S):2055 (2006). |
| Salamone, et al., “A Multi-Center Evaluation of a Rapid Immunoassay to Quantitate 5-Fluorouracil in Plasma”, 2008 HOPA Conference—Anaheim, California (Poster). |
| Sulkowska, et al., “Competitive Binding of Phenylbutazone and Colchicine to Serum Albumin in Multidrug Therapy: A Spectroscopic Study”, Journal of Molecular Structure, vol. 881:97-106 (2008). |
| Vandelinder, V. and A. Groisman, “Separation of Plasma from Whole Human Blood in a Continuous Cross-Flow in a Molded Microfluidic Device”, Anal. Chem., vol. 78:3765-3771 (2006). |
| Villamor, J. and A. Zatón, “Data Plotting of Warfarin Binding to Human Serum Albumin”, J. Biochem. Biophys. Methods, vol. 48:33-41 (2001). |
| Vos, et al., “Use of the Enzyme-Linked Immunosorbent Assay (ELISA) in Immunotoxicity Testing”, Environmental Health Perspectives, vol. 43:115-121 (1982). |
| Yamashita, et al., “5-Fluorouracil Derivatives with Serum Protein Binding Potencies”, Chem. Pharm. Bull., vol. 37 (10):2861-2863 (1989). |
| Yamashita, et al., “Possible Role of Serum Protein Binding to Improve Drug Disposition”, International Journal of Pharmaceutics, vol. 108:241-247 (1994). |
| Zsila, et al., “Evaluation of Drug-Human Serum Albumin Binding Interactions with Support Vector Machine Aided Online Automated Docking”, Bioinformatics, vol. 27(13):1806-1813 (2011). |
| The International Search Report and the Written Opinion from International PCT Application No. PCT/US2013/041252. |
| The International Search Report and the Written Opinion from International PCT Application No. PCT/US2013/041255. |
| The International Search Report and the Written Opinion from International PCT Application No. PCT/US2012/067041. |
| Restriction Requirement, dated Jun. 27, 2014, from co-pending U.S. Appl. No. 13/844,450. |
| Response to Jun. 27, 2014 Restriction Requirement, from co-pending U.S. Appl. No. 13/844,450. |
| Notice of Allowance and Fees Due, dated Oct. 22, 2014, from co-pending U.S. Appl. No. 13/844,450. |
| Notice of Allowance and Fees Due, dated Jan. 5, 2015, from co-pending U.S. Appl. No. 13/844,450. |
| Number | Date | Country | |
|---|---|---|---|
| 20130337432 A1 | Dec 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61647272 | May 2012 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US2012/067041 | Nov 2012 | US |
| Child | 13844527 | US |
